HIV vaccines and methods of using

Abstract

To provide HIV vaccines and methods of using.SOLUTION: Provided are HIV-1 fusion polypeptides, polynucleotides encoding such fusion polypeptides, vectors expressing such fusion polypeptides for use in eliciting an immune response against HIV-1; pharmaceutical and immunogenic compositions and kits comprising such fusion polypeptides, polynucleotides or vectors, and methods of use in treating and / or preventing HIV-1. Further provided are methods for design of antiviral vaccines, including vaccines to elicit an immune response against HIV-1.SELECTED DRAWING: None

Description

Technical Field

[0001] (Cross - Reference to Related Applications) This application claims the benefit of U.S. Provisional Patent Application No. 63 / 137,521, filed on January 14, 2021; U.S. Provisional Patent Application No. 63 / 149,820, filed on February 16, 2021; and U.S. Provisional Patent Application No. 63 / 170,900, filed on April 5, 2021, under 35 U.S.C. § 119(e), and these are hereby incorporated by reference in their entirety for all purposes. Sequence Listing

[0002] This application includes a sequence listing submitted electronically in ASCII format, which is hereby incorporated by reference in its entirety. The ASCII copy created on December 12, 2021, is named 1355 - WO - PCT.txt and is 512,244 bytes in size.

Background Art

[0003] HIV remains one of the leading causes of global morbidity and mortality, with over 38 million infections and 690,000 deaths worldwide in 2019 (UNAIDS. Fact Sheet - World AIDS Day 2020. unaidsorg / en / resources / fact-sheet. 2020). Over the past 30 years, there have been remarkable improvements in the treatment of HIV. The development of highly active antiretroviral therapy has improved the survival of people living with HIV and reduced the morbidity due to HIV-related immunosuppression and opportunistic infections (Johnson, et al., PLoS Med. 2013;10(4):e1001418; May, et al., AIDS. (2014)28(8):1193 - 202; Rodger, et al., AIDS. (2013)27(6):973 - 9; Samji, et al., PLoS One. (2013)8(12):e81355). In recent years, antiretroviral therapy (ART) regimens have been simplified to once-daily pills with long-acting oral agents and injectable therapeutics in the near future (Swindells, et al., N Engl J Med. (2020)382(12):1112 - 23; Orkin, et al., N Engl J Med. (2020)382(12):1124 - 35; Link, et al., Nature. (2020)584(7822):614 - 8). Despite these advances in treatment, to date, there have been only two well-documented cases of cure, both of which required severe immunosuppression and bone marrow transplantation (Gupta, et al., Lancet HIV. (2020)7(5):e340 - e7; Hutter, et al., N Engl J Med. (2009) 360(7):692 - 8). Different from many naturally curable infectious diseases, the HIV virus integrates itself into the host genome and establishes latency in resting memory CD4+ T cells (Eisele, et al., Immunity. (2012) 37(3):377 - 88). These cells form an HIV latency reservoir that cannot be removed by standard antiretroviral therapy. Reservoir cells also express no viral antigens that would enable them to evade recognition and clearance by cytotoxic T cells, and thus are protected from immune surveillance and clearance mechanisms. The reservoir is long - lived, and viral rebound is observed after the discontinuation of ART despite a detectable decrease in the size of the reservoir (Henrich, et al., Ann Intern Med. (2014) 161(5):319 - 27; Henrich, et al., J Infect Dis. (2013) 207(11):1694 - 702). Activation of the reservoir by latency - reversing agents needs to be combined with an effective mechanism to stimulate cytotoxic T cells and eliminate infected reservoir cells (Ait - Ammar, et al., Front Microbiol. (2019) 10:3060; Mothe, et al., Front Immunol. (2020) 11:823; Fidler, et al., Lancet. (2020) 395(10227):888 - 98). Therapeutic vaccines designed to generate antigen - specific effector T - cell responses could be a further component of an HIV cure strategy.

[0004] T cell vaccines are quite promising in therapeutic areas such as cancer. High levels of tumor-infiltrating CD8+ lymphocytes are associated with good prognosis in several cancers, and there is great interest in the development of vaccines that can induce tumor-specific cytotoxic CD8+ T cells. Previous approaches have achieved only limited success (Rosenberg, et al., Nature Medicine. (2004) 10(9):909-15), but the use of new delivery platforms and improved techniques in antigen discovery and immunomodulation can be expected to some extent (Ott, et al., Nature. (2017) 547(7662):217-21). Similarly, T cells play an important role in the control of HIV viremia. Antigen-specific T cells that arise during acute HIV infection are involved in driving the initial decline in viremia (Borrow, et al., J Virol. (1994) 68(9):6103-10; Koup, et al., J Virol. (1994) 68(7):4650-5). Human long-term non-progressors infected with HIV, i.e., elite controllers, are characterized by having a strong and effective antigen-specific T cell response. In SIV infection (a non-human primate model of human HIV infection), antigen-specific T cells generated by natural or vaccination are associated with viral control (Schmitz, et al., Science (1999) 283(5403):857-60; Jin, et al., J Exp Med. (1999) 189(6):991-8). Despite this data, T cell vaccines for prevention have had limited success in inducing limited-range or effective T cell responses (Buchbinder, et al., Lancet (2008) 372(9653):1881-93; Janes, et al., J Infect Dis. (2013) 208(8):1231-9; Excler, et al., Curr Opin HIV AIDS. (2016) 11(6):607-13). Trials of therapeutic vaccines using T cell vaccines have also shown limited efficacy (Mothe, et al., Front Immunol. (2020) 11:823; Colby, et al., Nature Medicine. (2020) 26(4):498-501). These trials have used viral vectors such as adenoviruses (human and chimpanzee) and modified vaccinia Ankara (MVA) virus, together with full-length viral antigens or shorter constructs (Barouch, et al., Lancet (2018) 392(10143):232-43; Mothe, et al., EClinicalMedicine. (2019) 11:65-80). Data from these trials suggest that the range of antigen-specific T cells generated after vaccination is narrow. These vaccine-induced T cells secrete IFN-γ in standard ELISpot assays, but the lack of demonstrated efficacy suggests that these T cells may not have full cytotoxic activity.

[0005] The design of immunogens is a component of any therapeutic HIV vaccine that targets conserved regions and generates an appropriate antigen-specific response with cytotoxic activity. Natural infection has demonstrated that the immune response tends to focus on highly immunodominant variable regions within HIV, such as in the HIV envelope or Nef, or variable regions in HIV Gag (Addo, et al. J Virol. (2003) 77(3):2081-92; Betts, et al., J Virol. 2001;75(24):11983-91). These responses generate T cells from which the virus can rapidly escape without fitness cost (Liu, et al., J Virol. (2006) 80(19):9519-29). An effective HIV vaccine needs to avoid these regions and drive the establishment of de novo responses that focus the immune response on conserved regions of the virus where conservation is required for maintenance of viral function. Previous HIV vaccines have mainly focused on designing immunogens that provide a universal scope by addressing the overall HIV virus diversity, adapting algorithms to generate full-length sequences or constructs of conserved regions (Korber, et al., Hum Vaccin Immunother. (2020) 16(3):713 - 722; Fischer, et al., Nature Medicine. (2007) 13(1):100 - 6). All of these approaches mainly evaluate consensus sequences that assess inter-patient variability to determine conserved regions and are concatenated to provide an overall sequence range. However, within an individual infected with HIV, there are several circulating quasi-species. Some of these viral quasi-species are generated as a result of T cell pressure and reflect existing escape routes of the virus where a T cell response directed against the virus should emerge (Liu, et al., J Virol. (2006) 80(19):9519 - 29; Korber, et al., 2020, supra; Price, et al., Proc Natl Acad Sci U S A. (1997) 94(5):1890 - 5). The failure of previous vaccines to target conserved regions while considering quasi-species along with the identification of highly conserved immunogenic regions may partially explain their limited effectiveness (Hanke, et al., Expert Rev Vaccines. (2019) 18(10):1029 - 41).

Prior Art Documents

Non-Patent Documents

[0006]

Non-Patent Document 1

Non-Patent Document 2

Non-Patent Document 3

Non - Patent Document 4

Non - Patent Document 5

Summary of the Invention

Means for Solving the Problems

[0007] Provided is a fusion polypeptide comprising a plurality of polypeptide segments of one or more human immunodeficiency virus type 1 (HIV-1) proteins encoded by two or more HIV genes selected from gag, pol, and nef. In some embodiments, the plurality of polypeptide segments comprises or consists of polypeptide segments encoded by the HIV-1 genes pol and nef and does not include polypeptide segments encoded by the HIV-1 genes env, tat, rev, vpr, vif, and / or vpu. In some embodiments, the plurality of polypeptide segments comprises or consists of polypeptide segments encoded by the HIV-1 genes gag, pol, and nef and does not include polypeptide segments encoded by the HIV-1 genes env, tat, rev, vpr, vif, and / or vpu. In some embodiments, the plurality of polypeptide segments is derived from a conserved region in a population of viral proteome sequences. In some embodiments, the conserved region is conserved at greater than 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% among HIV-1 subtypes in a population of patients. In some embodiments, the conserved region is conserved among one or more of HIV-1 clades A-K, such as one or more of clades A, B, C, D, and G, or one or more recombinant forms of one or more of HIV-1 clades A-K, and combinations thereof. In some embodiments, the fusion polypeptide comprises at least 4 and up to 6 polypeptide segments, such as 4, 5, or 6 polypeptide segments.In some embodiments, each polypeptide segment is at least 10 amino acids in length and up to about 225 amino acids in length, for example, from at least 10 amino acids in length up to 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 105, 110, 115, 120, 125, 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220 or 225 amino acids in length. In some embodiments, the full length of the fusion polypeptide comprises at least about 330 amino acids and up to about 505 amino acids (excluding the signal peptide) or up to about 550 amino acids (including the signal peptide), for example, at least about 330 amino acids and up to about 335, 340, 345, 350, 355, 360, 365, 370, 375, 380, 385, 390, 400, 405, 410, 415, 420, 425, 430, 435, 440, 445, 450, 455, 460, 465, 470, 475, 480, 485, 490, 495, 500, 505, 510, 515, 520, 525, 530, 535, 540, 545 or 550 amino acids. In some embodiments, the full length of the fusion polypeptide is 550 amino acids or less (with the signal peptide) or 505 amino acids or less (without the signal peptide), for example, 545, 540, 535, 530, 525, 520, 515, 510, 505, 500, 495, 490, 485, 480, 475, 470, 465, 460, 455, 450, 445, 440, 435, 430, 425, 420, 415, 410, 405, 400, 390, 385, 380, 375, 370, 365, 360, 355, 350, 345, 340, 335 or 330 amino acids or less. In some embodiments, the full length of the fusion polypeptide comprises at least 350 amino acids and up to 385 amino acids, for example, at least 350 amino acids and up to 365 amino acids.In some embodiments, the full length of the fusion polypeptide comprises at least 390 amino acids and at most 395 amino acids. In some embodiments, each polypeptide segment comprises or consists of one or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises three or more predicted T cell epitopes, such as four, five, six or more predicted T cell epitopes. In some embodiments, the fusion polypeptide comprises one or more polypeptide segments that bind to or are presented by one or more human HLA class I alleles (e.g., 1, 2, 3, 4, 5 or 6 alleles) within, for example, a single subject or among multiple patients. In some embodiments, the fusion polypeptide is at least human A. *It comprises one or more polypeptide segments that bind to or are presented by an HLA class I molecule. In some embodiments, the fusion polypeptide comprises, for example, one or more polypeptide segments that are intracellularly processed and presented by one or more human HLA class II alleles (e.g., 1, 2, 3, 4, 5, or 6 alleles) within a single subject. In some embodiments, one or more polypeptide segments are in contact with or fused to adjacent segments. In some embodiments, one or more of the polypeptide segments are linked to adjacent segments by one or more peptide linkers. In some embodiments, one or more peptide linkers are selected from one or more of polyalanine, polyglycine, Gln-Glu-Glu (QEE), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL), Leu-Ile-Lys (LIK), Pro-Pro-Val (PPV), Ser-Glu-Gly (SEG), cleavable linkers, flexible linkers, rigid linkers, and combinations thereof. In some embodiments, the flexible linker is selected from Gln-Glu-Glu (QEE) (SEQ ID NO: 51), lysine (L), isoleucine (I), Leu-Ile (LI), Lys-Ile-Leu (KIL) (SEQ ID NO: 52), Leu-Ile-Lys (LIK) (SEQ ID NO: 53), Pro-Pro-Val (PPV) (SEQ ID NO: 54), and Ser-Glu-Gly (SEG) (SEQ ID NO: 55). In some embodiments, the flexible linker comprises, or consists of, for example, 2 or 3 consecutive alanine residues, such as AA, AAA (SEQ ID NO: 48), AAY (SEQ ID NO: 49), or AAX (where X is any amino acid (e.g., A, C, D, E, F, G, H, I, K, L, M, N, P, Q, R, S, T, V, Y)) (SEQ ID NO: 50), a polyalanine linker or a polyglycine linker. In some embodiments, the flexible linker comprises, or consists of, GG, GGS (SEQ ID NO: 57), GSG (SEQ ID NO: 58), or GGGS (SEQ ID NO: 59).In some embodiments, the cleavable linker is selected from 2A cleavable peptides (e.g., foot-and-mouth disease virus (F2A), equine rhinitis A virus (E2A), porcine teschovirus-1 (P2A), and Thosea asigna virus (T2A)), furin recognition / cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives, or variants thereof. In some embodiments, the cleavable linker comprises or consists of a furin recognition / cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62). In some embodiments, the cleavable linker comprises or consists of an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), and comprises or consists of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the fusion polypeptide comprises two, three, four, five, six, or more of the polypeptide segments, and the polypeptide is Gag 1-53, Gag 147-369, Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 586-606, Pol 683-708, Pol 747-827, Pol 840-909, Pol 840-920, Pol. comprises or consists of amino acid residues corresponding to 932-1003, Nef 64-76, Nef 64-99 or Nef 117-148, wherein the amino acid position numbers of Gag, Pol and Nef correspond to SEQ ID NO: 1, 2 and 3 respectively. In some embodiments, the fusion polypeptide does not include any polypeptide segments corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116 and Nef 149-206, or fragments or subsequences thereof, wherein the amino acid position numbers of Gag, Pol and Nef correspond to SEQ ID NO: 1, 2 and 3 respectively. In some embodiments, the fusion polypeptide does not include a polypeptide segment having an amino acid sequence of any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NOs: 35-47, or a fragment or subsequence thereof. In some embodiments, the fusion polypeptide includes two, three, four, five, six, or more polypeptide segments selected from SEQ ID NOs: 4-33.In some embodiments, the fusion polypeptide comprises or consists of the following polypeptide segments, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NO: 1, 2, and 3, respectively: (a) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, and Nef 117-148; (b) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431, and Nef 64-99; (c) amino acid residues corresponding to Pol 542-606, Pol 747-827, Pol 840-920, Pol 932-1003, and Nef 64-99; (d) amino acid residues corresponding to Gag 1-53, Gag 147-369, Pol 683-708, Pol 747-827, Pol 840-920, and Nef 117-148; (e) amino acid residues corresponding to Pol 56-117, Pol 129-320, Pol 367-431, Pol 542-606, Pol 932-1003, and Nef 64-99; (f) Gag 147-369, Pol 586-606. Amino acid residues corresponding to Pol 683-708 and Pol 840-920; (g) Pol 129-320, Pol 747-827, Pol 932-1003, and Nef Amino acid residues corresponding to 64 - 76, or amino acid residues corresponding to (h)Gag: 147 - 369, Pol 747 - 827, Pol 840 - 909, and Nef 64 - 76. In some forms, the fusion polypeptide comprises or consists of the following polypeptide segments: (a) SEQ ID NO: 4, 6, 18, and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 4, 6, 18, and 32 respectively, (b) SEQ ID NO: 5, 7, 19, and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, 7, 19, and 33 respectively, (c) SEQ ID NO: 8, 10, 12, and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 8, 10, 12, and 30 respectively, (d) SEQ ID NO: 9, 11, 13, and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 9, 11, 13, and 31 respectively, (e) SEQ ID NO: 14, 20, 24, 26, and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 14, 20, 24, 26, and 30 respectively, (f) SEQ ID NO: 15, 21, 25, 27, and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 15, 21, 25, 27, and 31 respectively, (g) SEQ ID NO: 4, 6, 18,20, 24, and 32, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 4, 6, 18, 20, 24, and 32 respectively, (h) SEQ ID NO: 5, 7, 19, 21, 25, and 33, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 5, 7, 19, 21, 25, and 33 respectively, (i) SEQ ID NO: 8, 10, 12, 14, 26, and 30, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 8, 10, 12, 14, 26, and 30 respectively, (j) SEQ ID NO: 9, 11, 13, 15, 27, and 31, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 9, 11, 13, 15, 27, and 31 respectively, (k) SEQ ID NO: 6, 16, 18, and 24, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 6, 16, 18, and 24 respectively, (l) SEQ ID NO: 7, 17, 19, and 25, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to SEQ ID NO: 7, 17, 19, and 25 respectively, (m) SEQ ID NO: 10, 20, 26, and 28, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Array segments that are 98% or 99% identical, (n) SEQ ID NO: 11, 21, 27, and 29, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 11, 21, 27, and 29 respectively, (o) SEQ ID NO: 6, 20, 22, and 28, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 6, 20, 22, and 28 respectively, (p) SEQ ID NO: 7, 21, 23, and 29, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, 21, 23, and 29 respectively, (q) SEQ ID NO: 6, 16, 18, and 24, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 6, 16, 18, and 24 respectively, (r) SEQ ID NO: 7, 17, 19, and 25, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, 17, 19, and 25 respectively, (s) SEQ ID NO: 10, 20, 26, and 28, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 10, 20, 26, and 28 respectively, or, (t) SEQ ID NO: 11, 21, 27, and 29, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Array segments that are 98% or 99% identical. In some forms, the fusion polypeptide comprises, or consists of, the following polypeptide segments, optionally linked or connected by one or more linkers in order from the N-terminus to the C-terminus: SEQ ID NO: 6, 4, 18, and 32, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 6, 4, 18, and 32 respectively; SEQ ID NO: 7, 5, 33, and 19, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, 5, 33, and 19 respectively; SEQ ID NO: 12, 30, 8, and 10, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 12, 30, 8, and 10 respectively; SEQ ID NO: 9, 31, 13, and 11, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 9, 31, 13, and 11 respectively; SEQ ID NO: 14, 26, 20, 30, and 24, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 14, 26, 20, 30, and 24 respectively; SEQ ID NO: 15, 31, 21, 27, and 25, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 15, 31, 21, 27, and 25 respectively; SEQ ID NO: 32, 18, 4, and 6, or array segments that are at least 80%, 81%,Array segments that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 7, 33, 5 and 19, or SEQ ID NO: 7, 33, 5 and 19 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 8, 30, 12 and 10, or SEQ ID NO: 8, 30, 12 and 10 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 13, 31, 9 and 11, or SEQ ID NO: 13, 31, 9 and 11 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 26, 30, 14, 20 and 24, or SEQ ID NO: 26, 30, 14, 20 and 24 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 31, 27, 15, 25 and 21, or SEQ ID NO: 31, 27, 15, 25 and 21 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 24, 6, 4, 20, 18 and 32, or SEQ ID NO: 24, 6, 4, 20, 18 and 32 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 6, 20, 4, 24, 32 and 18, or SEQ ID NO: 6, 20, 4, 24, 32 and 18 and array segments that are at least 80%, 81%,82%、83%、84%、85%、86%、87%、88%、89%、90%、91%、92%、93%、 sequence segments that are 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 7, 21, 5, 25, 33 and 19, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, 21, 5, 25, 33 and 19 respectively, SEQ ID NO: 8, 30, 14, 12, 26 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 8, 30, 14, 12, 26 and 10 respectively, SEQ ID NO: 8, 12, 30, 26, 14 and 10, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 8, 12, 30, 26, 14 and 10 respectively, SEQ ID NO: 9, 13, 31, 27, 15 and 11, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 9, 13, 31, 27, 15 and 11 respectively, SEQ ID NO: 20, 32, 24, 4, 6 and 18, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 20, 32, 24, 4, 6 and 18 respectively, SEQ ID NO: 7, 25, 19, 5, 33 and 21, or sequence segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, 25, 19, 5, 33 and 21 respectively, SEQ ID NO: 26, 30, 12, 14, 8 and 10, or sequence segments that are at least 80%, 81%, 82%,Array segments that are 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 15, 31, 9, 27, 13 and 11, or SEQ ID NOs: 15, 31, 9, 27, 13 and 11 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 24, 6, 16 and 18, or SEQ ID NOs: 24, 6, 16 and 18 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 7, 19, 17 and 25, or SEQ ID NOs: 7, 19, 17 and 25 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 24, 16, 6 and 18, or SEQ ID NOs: 24, 16, 6 and 18 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 7, 25, 17 and 19, or SEQ ID NOs: 7, 25, 17 and 19 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 26, 20, 10 and 28, or SEQ ID NOs: 26, 20, 10 and 28 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 21, 27, 11 and 29, or SEQ ID NOs: 21, 27, 11 and 29 and array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%,Array segments that are 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 26, 10, 20 and 28, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 26, 10, 20 and 28 respectively, SEQ ID NO: 11, 27, 21 and 29, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 11, 27, 21 and 29 respectively, SEQ ID NO: 22, 6, 20 and 28, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 22, 6, 20 and 28 respectively, SEQ ID NO: 23, 7, 21 and 29, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 23, 7, 21 and 29 respectively, SEQ ID NO: 22, 20, 6 and 28, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 22, 20, 6 and 28 respectively, or SEQ ID NO: 7, 21, 23 and 29, or array segments that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 7, 21, 23 and 29 respectively. In some embodiments, the fusion polypeptide is any one amino acid sequence of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or SEQ ID NOs: 70-101, 105-112,Comprising or consisting of an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of 200 - 209, 222 - 223, and 227. In some embodiments, the fusion polypeptide comprises or consists of an amino acid sequence of any one of SEQ ID NOs: 82 - 83, 85 - 87, 98 - 101, 209, and 222 - 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82 - 83, 85 - 87, 98 - 101, 209, and 222 - 223.

[0008] There is further provided a composite fusion polypeptide comprising at least a first fusion polypeptide and a second fusion polypeptide, wherein the first and second fusion polypeptides are selected independently from the fusion polypeptides described above and herein. In some embodiments, the composite fusion polypeptide comprises or consists of the following first and second fusion polypeptides optionally linked or connected by one or more linkers: SEQ ID NOs: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 70 or 71; SEQ ID NOs: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 72 or 73; SEQ ID NOs: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 74 or 75; SEQ ID NOs: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 76 or 77; SEQ ID NOs: 78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 78 or 79; SEQ ID NOs: 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NOs: 82 and 83, or either one of SEQ ID NOs: 82 and 83, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 84 and 85, or either one of SEQ ID NOs: 84 and 85, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 86 and 87, or either one of SEQ ID NOs: 86 and 87, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 88 and 89, or either one of SEQ ID NOs: 88 and 89, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 82 and 85, or either one of SEQ ID NOs: 82 and 85, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 82 and 86, or either one of SEQ ID NOs: 82 and 86, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 82 and 88, or either one of SEQ ID NOs: 82 and 88, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of them, SEQ ID NOs: 83 and 87,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 83 and 87, SEQ ID NO: 85 and 87, or any one of SEQ ID NO: 85 and 87; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 88 and 87, SEQ ID NO: 88 and 87; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 84 and 88, SEQ ID NO: 84 and 88; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 85 and 89, SEQ ID NO: 85 and 101, SEQ ID NO: 85 and 89, SEQ ID NO: 85 and 101; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 90 and 91, SEQ ID NO: 90 and 91; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to any one of SEQ ID NO: 92 and 93, SEQ ID NO: 92 and 93,A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 94 and 95, or either one of SEQ ID NOs: 94 and 95 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 96 and 97, or either one of SEQ ID NOs: 96 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 94 and 96, or either one of SEQ ID NOs: 94 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 95 and 97, or either one of SEQ ID NOs: 95 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 220 and 221, or either one of SEQ ID NOs: 220 and 221 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 98 and 100, or either one of SEQ ID NOs: 98 and 100 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 99 and 101, or either one of SEQ ID NOs: 99 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,A fusion polypeptide that is 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or 99, respectively, or SEQ ID NO: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 100 or 101, respectively. In some embodiments, the composite fusion polypeptide comprises, or consists of, the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers, in order from the N-terminus to the C-terminus: SEQ ID NO: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 70 or 71, respectively, SEQ ID NO: 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 71 or 70, respectively, SEQ ID NO: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 72 or 73, respectively, SEQ ID NO: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 73 or 72, respectively, SEQ ID NO: 74 and 75,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 74 or 75, SEQ ID NO: 75 and 74, or either SEQ ID NO: 75 and 74 and at least 8 each, A fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 76 and 77, or either one of SEQ ID NO: 76 and 77 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, a fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 77 and 76, or either one of SEQ ID NO: 77 and 76 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, a fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 78 and 79, or either one of SEQ ID NO: 78 and 79 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, a fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 79 and 78, or either one of SEQ ID NO: 79 and 78 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, a fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 80 and 81, or either one of SEQ ID NO: 80 and 81 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, a fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 81 and 80, or either one of SEQ ID NO: 81 and 80 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, a fusion polypeptide that is 0%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 82 and 83, or either one of SEQ ID NO: 82 and 83 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,A fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 83 and 82, or either one of SEQ ID NO: 83 and 82 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 84 and 85, or either one of SEQ ID NO: 84 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 85 and 84, or either one of SEQ ID NO: 85 and 84 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 86 and 87, or either one of SEQ ID NO: 86 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 87 and 86, or either one of SEQ ID NO: 87 and 86 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 88 and 89, or either one of SEQ ID NO: 88 and 89 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 89 and 88, or either one of SEQ ID NO: 89 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively,A fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 82 and 85, or either one of SEQ ID NO: 82 and 85; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 85 and 82, or either one of SEQ ID NO: 85 and 82; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 82 and 86, or either one of SEQ ID NO: 82 and 86; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 86 and 82, or either one of SEQ ID NO: 86 and 82; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 82 and 88, or either one of SEQ ID NO: 82 and 88; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 88 and 82, or either one of SEQ ID NO: 88 and 82; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 83 and 87, or either one of SEQ ID NO: 83 and 87; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%,A fusion polypeptide that is 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 87, or any one of SEQ ID NO: 85 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 87 and 85, or any one of SEQ ID NO: 87 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 88 and 87, or any one of SEQ ID NO: 88 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 87 and 88, or any one of SEQ ID NO: 87 and 88 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 84 and 88, or any one of SEQ ID NO: 88 and 84 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 88 and 84, or any one of SEQ ID NO: 88 and 84 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 89, or any one of SEQ ID NO: 85 and 89 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NO: 89 and 85, or either one of SEQ ID NO: 89 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 85 and 101, or either one of SEQ ID NO: 85 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 101 and 85, or either one of SEQ ID NO: 101 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 90 and 91, or either one of SEQ ID NO: 90 and 91 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 91 and 90, or either one of SEQ ID NO: 91 and 90 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 92 and 93, or either one of SEQ ID NO: 92 and 93 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 93 and 92, or either one of SEQ ID NO: 93 and 92 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 94 and 95,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NO: 94 and 95, SEQ ID NO: 95, and 94, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 95 and 94, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 97 and 96, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 94 and 96, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 96 and 94, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 95 and 97, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 97 and 95, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 220 and 221, or a fusion polypeptide that is at least 80%, 81%,A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 221 and 220, or either one of SEQ ID NO: 221 and 220 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 100, or either one of SEQ ID NO: 98 and 100 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 100 and 98, or either one of SEQ ID NO: 100 and 98 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 99 and 101, or either one of SEQ ID NO: 99 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 101 and 99, or either one of SEQ ID NO: 101 and 99 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 99 and 98, or either one of SEQ ID NO: 99 and 98 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,A fusion polypeptide that is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 100 and 101, or either one of SEQ ID NO: 100 and 101, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each, or a fusion polypeptide that is 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 101 and 100, or either one of SEQ ID NO: 101 and 100, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are linked or connected by a cleavable linker. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are linked or connected by a cleavable linker selected from 2A cleavage peptides (e.g., Foot-and-Mouth Disease Virus (F2A), Equine rhinitis A virus (E2A), Porcine teschovirus-1 (P2A) and Thosea asigna virus (T2A)), furin recognition / cleavage sequences (e.g., RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61), and RRKR (SEQ ID NO: 62)), and combinations, derivatives or variants thereof. In some embodiments, the first fusion polypeptide and the second fusion polypeptide are linked or connected by a furin recognition / cleavage site selected from RAKR (SEQ ID NO: 60), REKR (SEQ ID NO: 61) and RRKR (SEQ ID NO: 62). In some embodiments, the first fusion polypeptide and the second fusion polypeptide comprise or consist of the amino acid sequence of ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63), APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67), or ATNFSLLKQAGDVEENPGP (SEQ ID NO: 63),It is linked or connected by a 2A-cleavable peptide having an amino acid sequence that is at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or at least 99% identical to APVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 64), RAKRAPVKQTLNFDLLKLAGDVESNPGP (SEQ ID NO: 65), QCTNYALLKLAGDVESNPGP (SEQ ID NO: 66), or EGRGSLLTCGDVEENPGP (SEQ ID NO: 67). In some embodiments, the complex fusion polypeptide comprises, or consists of, an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the complex fusion polypeptide comprises, or consists of, an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223.,

[0009] Regarding further embodiments of the fusion polypeptide and the complex fusion polypeptide, in some embodiments, the fusion polypeptide or the complex fusion polypeptide further comprises an N-terminal signal peptide or leader sequence. In some embodiments, the signal peptide or leader sequence is derived from a source protein selected from serum proteins, cytokines, chemokines, chaperone proteins, invariant proteins, and proteins that target proteins to the lysosomal compartment. In some embodiments, the signal peptide or leader sequence is derived from a source protein selected from the group consisting of colony-stimulating factor 2 (CSF2, GM-CSF), tissue-type plasminogen activator (PLAT, t-PA), C-C motif chemokine ligand 7 (CCL7, MCP-3), C-X-C motif chemokine ligand 10 (CXCL10, IP-10), catenin beta 1 (CTNNB1), CD74 (p33; DHLAG; HLADG; Ia-gamma, invariant chain), serum albumin (ALB), polyubiquitin B / C (UBB / UBC), calreticulin (CALR), vesicular stomatitis virus G protein (VSV-G), lysosome-associated membrane protein 1 (LAMP-1), and lysosome-associated membrane protein 2 (LAMP-2). In some embodiments, the signal peptide or leader sequence is selected from any one of the amino acid sequences of SEQ ID NOs: 115 to 126, or an amino acid sequence that is at least 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 115 to 126. In some embodiments, the fusion polypeptide and / or the complex fusion polypeptide is recombinantly produced or chemically synthesized. In some embodiments, the fusion polypeptide and / or the complex fusion polypeptide can induce, enhance, or stimulate an immune response in humans. In some embodiments, the fusion polypeptide and / or the complex fusion polypeptide can induce, enhance, or stimulate an immune response against HIV-1 in humans.In some embodiments, the fusion polypeptide and / or the complex fusion polypeptide can induce, promote, or stimulate the proliferation and / or activation of one or more cell types selected from monocyte-derived dendritic cells (DCs), CD8+ T cells, and CD4+ T cells.

[0010] There is further provided a polynucleotide encoding one or more fusion polypeptides or complex fusion polypeptides as described above and herein. In some embodiments, the polynucleotide comprises cDNA, mRNA, self-amplifying RNA, (SAM, saRNA), self-replicating RNA, or self-amplifying replicon RNA (RepRNA). In some embodiments, the polynucleotide comprises a self-replicating or self-amplifying alphavirus replicon. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the polynucleotide comprises a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. There is further provided an expression cassette comprising one or more polynucleotides as described herein operably linked to one or more regulatory sequences, such as a promoter. In some embodiments, the polynucleotide is operably linked to and under the control of a constitutive promoter. In some embodiments, the promoter is selected from the CMV promoter, the CAG promoter, and the EF1a promoter.

[0011] Lipoplexes, such as lipid nanoparticles (LNPs), are further provided, which encode one or more polypeptides having an amino acid sequence of any one of, for example, SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, one or more polynucleotides described herein, such as a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226.In some embodiments, a lipoplex, such as a lipid nanoparticle (LNP), comprises one or more polynucleotides described herein that encode one or more polypeptides having an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, for example, a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226.

[0012] There is further provided a vector comprising one or more polynucleotides and one or more expression cassettes. In some embodiments, the vector comprises or consists of one or more polynucleotides encoding one or more fusion polypeptides comprising the following polypeptide segments optionally linked or connected by one or more linkers in order from the N-terminus to the C-terminus: SEQ ID NO: 6, 4, 16, and 26, and SEQ ID NO: 7, 5, 27, and 17, SEQ ID NO: 12, 24, 8, and 10, and SEQ ID NO: 9, 25, 13, and 11, SEQ ID NO: 14, 22, 18, 24, and 20, and SEQ ID NO: 15, 25, 19, 23, and 21, SEQ ID NO: 26, 16, 4, and 6, and SEQ ID NO: 7, 27, 5, and 17, SEQ ID NO: 8, 24, 12, and 10, and SEQ ID NO: 13, 25, 9, and 11, SEQ ID NO: 22, 24, 14, 18, and 20, and SEQ ID NO: 25, 23, 15, 21, and 19, SEQ ID NO: 20, 6, 4, 18, 16, and 26, and SEQ ID NO: 7, 19, 5, 21, 27, and 17, SEQ ID NO: 8, 24, 14, 12, 22, and 10, and SEQ ID NO: 9, 13, 25, 23, 15, and 11, SEQ ID NO: 18, 26, 20, 4, 6, and 16, and SEQ ID NO: 7, 21, 17, 5, 27, and 19, SEQ ID NO: 22, 24, 12, 14, 8, and 10, and SEQ ID NO: 15, 25, 9, 23, 13, and 11, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 8, 30, 14, 12, 26, and 10, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 7, 21, 5, 25, 33, and 19, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 8, 30, 14, 12, 26, and 10, SEQ ID NO: 8, 30, 14, 12, 26, and 10, and SEQ ID NO: 9, 13, 31, 27, 15, and 11, SEQ ID NO: 6, 20, 4, 24, 32, and 18, and SEQ ID NO: 8, 12, 30, 26, 14, and 10, SEQ ID NO: 7, 21, 5, 25, 33, and 19, and SEQ ID NO: 9, 13, 31, 27, 15, and 11, SEQ ID NO: 20, 32, 24, 4, 6, and 18, and SEQ ID NO: 26, 30, 12, 14, 8, and 10, SEQ ID NO: 7, 25, 19, 5, 33, and 21, and SEQ ID NO: 15, 31, 9, 27, 13, and 11, SEQ ID NO: 24, 6, 16, and 18,and SEQ ID NO: 26, 20, 10, and 28, SEQ ID NO: 24, 6, 16, and 18, and SEQ ID NO: 26, 10, 20, and 28, SEQ ID NO: 24, 6, 16, and 18, and SEQ ID NO: 7, 25, 17, and 19, SEQ ID NO: 7, 19, 17, and 25, and SEQ ID NO: 21, 27, 11, and 29, SEQ ID NO: 24, 16, 6, and 18, and SEQ ID NO: 27, 11, 21, and 29, SEQ ID NO: 7, 25, 17, and 19, and SEQ ID NO: 11, 27, 21, and 29, SEQ ID NO: 7, 25, 17, and 19, and SEQ ID NO: 21, 27, 11, and 29, SEQ ID NO: 22, 6, 20, and 28, and SEQ ID NO: 23, 7, 21, and 29, SEQ ID NO: 22, 20, 6, and 28, and SEQ ID NO: 7, 21, 23, and 29, SEQ ID NO: 26, 10, 20, and 28, and SEQ ID NO: 21, 27, 11, and 29, SEQ ID NO: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or consisting of these. In some embodiments, the vector comprises one or more polynucleotides encoding one or more fusion polypeptides comprising an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or consisting of these. In some embodiments, the vector isOne or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NO: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 70 or 71; SEQ ID NO: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 72 or 73; SEQ ID NO: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 74 or 75; SEQ ID NO: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 76 or 77; SEQ ID NO: 78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 78 or 79; SEQ ID NO: 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 80 or 81; SEQ ID NO: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,A fusion polypeptide that is 96%, 97%, 98% or 99% identical, SEQ ID NO: 84 and 85, or any one of SEQ ID NO: 84 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 86 and 87, or any one of SEQ ID NO: 86 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 88 and 89, or any one of SEQ ID NO: 88 and 89 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 85, or any one of SEQ ID NO: 82 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 86, or any one of SEQ ID NO: 82 and 86 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 88, or any one of SEQ ID NO: 82 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 83 and 87, or any one of SEQ ID NO: 83 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 85 and 87,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 89, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 101, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 90 or 91, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 92 or 93, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%,A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 96 and 97, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 8, respectively, with either one of SEQ ID NOs: 96 and 97 A fusion polypeptide that is 9%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 94 and 96, or either one of SEQ ID NO: 94 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 95 and 97, or either one of SEQ ID NO: 95 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 220 and 221, or either one of SEQ ID NO: 220 and 221 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 100, or either one of SEQ ID NO: 98 and 100 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 99 and 101, or either one of SEQ ID NO: 99 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, or SEQ ID NO: 100 and 101, or either one of SEQ ID NO: 100 and 101 and each is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,A fusion polypeptide that is 97%, 98% or 99% identical. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers, in order from the N-terminus to the C-terminus: SEQ ID NO: 70 and 71, or either one of SEQ ID NO: 70 and 71 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 71 and 70, or either one of SEQ ID NO: 71 and 70 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 72 and 73, or either one of SEQ ID NO: 72 and 73 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 73 and 72, or either one of SEQ ID NO: 73 and 72 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 74 and 75, or either one of SEQ ID NO: 74 and 75 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 75 and 74, or either one of SEQ ID NO: 75 and 74 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 76 and 77, or either one of SEQ ID NO: 76 and 77 and a fusion polypeptide that is at least 80%, 81%,A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 77 and 76, or either one of SEQ ID NO: 77 and 76 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 78 and 79, or either one of SEQ ID NO: 78 and 79 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 79 and 78, or either one of SEQ ID NO: 79 and 78 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 80 and 81, or either one of SEQ ID NO: 80 and 81 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 81 and 80, or either one of SEQ ID NO: 81 and 80 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 82 and 83, or either one of SEQ ID NO: 82 and 83 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NO: 83 and 82, or either one of SEQ ID NO: 83 and 82 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,A fusion polypeptide that is 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 84 and 85, or any one of SEQ ID NO: 84 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 85 and 84, or any one of SEQ ID NO: 85 and 84 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 86 and 87, or any one of SEQ ID NO: 86 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 87 and 86, or any one of SEQ ID NO: 87 and 86 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 88 and 89, or any one of SEQ ID NO: 88 and 89 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 89 and 88, or any one of SEQ ID NO: 89 and 88 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 82 and 85, or any one of SEQ ID NO: 82 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide,A fusion polypeptide that is identical to SEQ ID NO: 85 and 82, or either one of SEQ ID NO: 85 and 82, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 82 and 86, or either one of SEQ ID NO: 82 and 86, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 86 and 82, or either one of SEQ ID NO: 86 and 82, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 82 and 88, or either one of SEQ ID NO: 82 and 88, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 88 and 82, or either one of SEQ ID NO: 88 and 82, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 83 and 87, or either one of SEQ ID NO: 83 and 87, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 87 and 83, or either one of SEQ ID NO: 87 and 83, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 85 and 87, or either one of SEQ ID NO: 85 and 87, respectively, by at least 80%, 81%,A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 87 and 85, or at least 80% with either one of SEQ ID NO: 87 and 85 respectively, , a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 88 and 87, or either one of SEQ ID NO: 88 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 87 and 88, or either one of SEQ ID NO: 87 and 88 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 84 and 88, or either one of SEQ ID NO: 88 and 84 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 88 and 84, or either one of SEQ ID NO: 88 and 84 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 85 and 89, or either one of SEQ ID NO: 85 and 89 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 89 and 85, or either one of SEQ ID NO: 89 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 85 and 101, or either one of SEQ ID NO: 85 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,A fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 101 and 85, or either one of SEQ ID NO: 101 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 90 and 91, or either one of SEQ ID NO: 90 and 91 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 91 and 90, or either one of SEQ ID NO: 91 and 90 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 92 and 93, or either one of SEQ ID NO: 92 and 93 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 93 and 92, or either one of SEQ ID NO: 93 and 92 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 94 and 95, or either one of SEQ ID NO: 94 and 95 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 95 and 94, or either one of SEQ ID NO: 95 and 94 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NO: 96 and 97, or either one of SEQ ID NO: 96 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 97 and 96, or either one of SEQ ID NO: 97 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 94 and 96, or either one of SEQ ID NO: 94 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 96 and 94, or either one of SEQ ID NO: 96 and 94 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 95 and 97, or either one of SEQ ID NO: 95 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 97 and 95, or either one of SEQ ID NO: 97 and 95 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 220 and 221, or either one of SEQ ID NO: 220 and 221 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 221 and 220,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 221 and 220, SEQ ID NO: 98 and 100, or SEQ ID NO: 98 and 100; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 100 and 98, or SEQ ID NO: 100 and 98; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 99 and 101, or SEQ ID NO: 99 and 101; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 101 and 99, or SEQ ID NO: 101 and 99; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 98 and 99, or SEQ ID NO: 98 and 99; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 99 and 98, or SEQ ID NO: 99 and 98; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 100 and 101, or SEQ ID NO: 100 and 101; or at least 80%,A fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 101 and 100, or either SEQ ID NO: 101 or 100. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 82 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 83. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or 85. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 86 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 86 or 87. In some embodiments, the vector isOne or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NO: 88 and 89, or any one of SEQ ID NO: 88 and 89 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, A fusion polypeptide. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 and 85. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 and 86. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 and 88. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 and 87.In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 87. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 87. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 84 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or 88. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 89.In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NO: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 101. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NO: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 90 or 91. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NO: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 92 or 93. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers: SEQ ID NO: 94 and 96, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 96.In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 95. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 95 or 97. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 220 or 221. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 96 or 97.In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 98 and 99, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 and 99. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 and 100. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 99 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 99 and 101. In some embodiments, the vector comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 100 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 100 and 101.In some embodiments, the vector comprises, or consists of, a polynucleotide encoding a complex fusion polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227. In some embodiments, the vector encodes a complex fusion polypeptide comprising an amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223. It contains the polynucleotide to be made. In some embodiments, the first and second fusion polypeptides do not include Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or any polypeptide segment corresponding to these fragments or subsequences, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, the first and second fusion polypeptides do not include the amino acid sequences of SEQ ID NOs: 35-47, or their fragments or subsequences, or any amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47, or their fragments or subsequences. In some embodiments, the vector contains, or consists of, a polynucleotide that is any one of the nucleic acid sequences of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the vector contains, oror a polynucleotide comprising these. In some embodiments, the following first polynucleotide and second polynucleotide: SEQ ID NO: 130 and 132, or any one of SEQ ID NO: 130 and 132 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 130 and 134, or any one of SEQ ID NO: 130 and 134 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 131 and 133, or any one of SEQ ID NO: 131 and 133 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 131 and 135, or any one of SEQ ID NO: 131 and 135 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 132 and 136, or any one of SEQ ID NO: 132 and 136 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 133 and 135, or any one of SEQ ID NO: 133 and 135 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, SEQ ID NO: 133 and 137, or any one of SEQ ID NO: 133 and 137 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,Polynucleotides that are 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 134 and 136, or either one of SEQ ID NOs: 134 and 136 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 135 and 137, or either one of SEQ ID NOs: 135 and 137 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 138 and 141, or either one of SEQ ID NOs: 138 and 141 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 138 and 144, or either one of SEQ ID NOs: 138 and 144 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 139 and 142, or either one of SEQ ID NOs: 139 and 142 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 139 and 145, or either one of SEQ ID NOs: 139 and 145 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 140 and 146, or either one of SEQ ID NOs: 140 and 146 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 142 and 148, or either one of SEQ ID NOs: 142 and 148 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 143 and 149, or either one of SEQ ID NOs: 143 and 149 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 145 and 148, or either one of SEQ ID NOs: 145 and 148 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 150 and 152, or either one of SEQ ID NOs: 150 and 152 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 150 and 155, or either one of SEQ ID NOs: 150 and 155 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 151 and 153, or either one of SEQ ID NOs: 151 and 153 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 151 and 156, or either one of SEQ ID NOs: 151 and 156 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 152 and 158, or either one of SEQ ID NOs: 152 and 158 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 153 and 159, or either one of SEQ ID NOs: 153 and 159 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 154 and 157, or either one of SEQ ID NOs: 154 and 157 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 155 and 158, or either one of SEQ ID NOs: 155 and 158 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 156 and 159, or either one of SEQ ID NOs: 156 and 159 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 160 and 161, or either one of SEQ ID NOs: 160 and 161 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 162 and 163, or either one of SEQ ID NOs: 162 and 163 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 164 and 165, or either one of SEQ ID NOs: 164 and 165 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NOs: 166 and 167, and, is a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 166 and 167, SEQ ID NOs: 210 and 211, or either of SEQ ID NOs: 210 and 211; is a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 212 and 213, SEQ ID NOs: 214 and 215, or either of SEQ ID NOs: 214 and 215; is a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 216 and 217, SEQ ID NOs: 218 and 219, or either of SEQ ID NOs: 218 and 219; is a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 218 and 226, SEQ ID NOs: 225 and 226, or either of SEQ ID NOs: 225 and 226Or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 225 or SEQ ID NO: 226. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 130 or SEQ ID NO: 131, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 130 or SEQ ID NO: 131 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 134 or SEQ ID NO: 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 134 or SEQ ID NO: 135. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 132 or SEQ ID NO: 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 132 or SEQ ID NO: 133 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 136 or SEQ ID NO: 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 136 or SEQ ID NO: 137. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 139, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%,Polynucleotides that are 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 145. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 142, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 142 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 148. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 140, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 140 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 146. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 143, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,Polynucleotides that are 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 149. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 150, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 150 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 152. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 151, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 151 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 153. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 154, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,polynucleotides that are 97%, 98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 157, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 157. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 155, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 155 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 158. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 156, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 156 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 159. In some embodiments, the vector comprises the following first and second polynucleotides: (a) a first polynucleotide comprising SEQ ID NO: 160, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,a polynucleotide that is 98% or 99% identical, and (b) a second polynucleotide comprising SEQ ID NO: 161, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161, A polynucleotide. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 166, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166 respectively, and (b) a second polynucleotide comprising SEQ ID NO: 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167.In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, and (b) a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, and (b) a second polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, and (b) a second polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215.In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, and (b) a second polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219. In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226.In some embodiments, the vector comprises the following first polynucleotide and second polynucleotide: (a) a first polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, and (b) a second polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are within a single open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is within a first open reading frame, and the second polynucleotide encoding the second fusion polypeptide is within a second open reading frame. In some embodiments, the first polynucleotide encoding the first fusion polypeptide and the second polynucleotide encoding the second fusion polypeptide are within a single expression cassette. In some embodiments, the first polynucleotide encoding the first fusion polypeptide is within a first expression cassette, and the second polynucleotide encoding the second fusion polypeptide is within a second expression cassette. In some embodiments, the vector is a plasmid vector, a bacterial vector, or a viral vector. In some embodiments, the vector is a viral vector. In some embodiments, the viral vector is a DNA virus or an RNA virus. In some embodiments, the viral vector is replication-deficient, replication-deleted, replication-attenuated, or replication-competent.In some embodiments, the viral vector is derived from a virus selected from adenovirus, adeno-associated virus, arenavirus, alphavirus, poxvirus, cytomegalovirus, rhabdovirus, vesicular stomatitis virus, flavivirus, maraba virus, and vaccinia virus. In some embodiments, the viral vector is derived from a virus belonging to a taxonomic family selected from the Adenoviridae, Arenaviridae, Herpesviridae (e.g., cytomegalovirus), Poxviridae (e.g., vaccinia virus, e.g., modified vaccinia Ankara (MVA)), Flaviviridae (e.g., yellow fever virus), Rhabdoviridae (e.g., vesiculovirus, e.g., Maraba vesiculovirus), Togaviridae (e.g., alphavirus, e.g., Venezuelan equine encephalitis virus). In some embodiments, the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammarenavirus (LCMV), Calomys callosus mammarenavirus (also known as Pichinde mammarenavirus or Pichinde arenavirus), Guanarito virus (GTOV), Junin virus (JUNV), Lassa virus (LASV), Lujo virus (LUJV), Machupo virus (MACV), Sabia virus (SABV), and Whitewater Arroyo virus (WWAV). In some embodiments, the viral vector is an arenavirus vector selected from lymphocytic choriomeningitis mammarenavirus (LCMV) or Calomys callosus mammarenavirus (also known as Pichinde mammarenavirus or Pichinde arenavirus). In some embodiments, the arenavirus vector comprises a two-segmented genome. In some embodiments, the arenavirus vector comprises a three-segmented genome. In some embodiments, the viral vector is a human adenovirus or a simian adenovirus (e.g., chimpanzee adenovirus, gorilla adenovirus, or rhesus adenovirus).In some embodiments, the viral vector is an adenovirus vector selected from adenovirus serotype 5 (Ad5), adenovirus serotype 26 (Ad26), adenovirus serotype 34 (Ad34), adenovirus serotype 35 (Ad35), adenovirus serotype 48 (Ad48), chimpanzee adenovirus (e.g., ChAd3 (AdC3), ChAd5 (AdC5), ChAd6 (AdC6), ChAd7 (AdC7), ChAd8 (AdC8), ChAd9 (AdC9), ChAd10 (AdC10), ChAd11 (AdC11), ChAd17 (AdC17), ChAd16 (AdC16), ChAd19 (AdC19), ChAd20 (AdC20), ChAd22 (AdC22), ChAd24 (AdC24), ChAdY25, ChAd26 (AdC26), ChAd28 (AdC28), ChAd30 (AdC30), ChAd31 (AdC31), ChAd37 (AdC37), ChAd38. (AdC38), ChAd43 (AdC43), ChAd44 (AdC44), ChAd55 (AdC55), ChAd63 (AdC63), ChAdV63, ChAd68 (AdC68), ChAd73 (AdC73), ChAd82 (AdC82), ChAd83 (AdC83), ChAd143 (AdC143), ChAd144 (AdC144), ChAd145 (AdC145), ChAd147 (AdC147)), gorilla adenovirus (e.g., GC44, GC45, GC46) and rhesus adenovirus (e.g., RhAd51, RhAd52, RhAd53, RhAd54, RhAd55, RhAd56, RhAd57, RhAd58, RhAd59, RhAd60, RhAd61, RhAd62, RhAd63, RhAd64, RhAd65, RhAd66).

[0013] Also provided is a host cell comprising one or more polynucleotides, one or more expression cassettes, or one or more vectors as described herein. In some embodiments, the one or more polynucleotides are not integrated into the host cell genome and are, for example, episomal. In some embodiments, the one or more polynucleotides are integrated into the host cell genome. In some embodiments, the host cell is a mammalian cell, such as a human cell. In various embodiments, the host cell can be in vitro or in vivo.

[0014] An immunogenic composition is further provided. In various embodiments, the immunogenic composition comprises one or more fusion polypeptides or composite fusion polypeptides, one or more polynucleotides, or one or more vectors as described herein, and a pharmaceutically acceptable carrier. Some embodiments include the immunogenic composition comprising two or more of the fusion polypeptides or composite fusion polypeptides described herein, two or more polynucleotides, two or more vectors. In some embodiments, the one or more polynucleotides are DNA, cDNA, mRNA, or self-replicating RNA. In some embodiments, the immunogenic composition comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors encoding the first and second fusion polypeptides, wherein the first and second polypeptides comprise the following polypeptide segments linked or joined optionally by one or more linkers in order from the N-terminus to the C-terminus: SEQ ID NO: 6, 4, 16, and 26, and SEQ ID NO: 7, 5, 27, and 17, SEQ ID NO: 12, 24, 8, and 10, and SEQ ID NO: 9, 25, 13, and 11, SEQ ID NO: 14, 22, 18, 24, and 20, and SEQ ID NO: 15, 25, 19, 23, and 21, SEQ ID NO: 26, 16, 4, and 6, and SEQ ID NO: 7, 27, 5, and 17, SEQ ID NO: 8, 24, 12, and 10, and SEQ ID NO: 13, 25, 9, and 11, SEQ ID NO: 22, 24, 14, 18, and 20, and SEQ ID NO: 25, 23, 15, 21, and 19, SEQ ID NO: 20, 6, 4, 18, 16, and 26, and SEQ ID NO: 7, 19, 5, 21, 27, and 17, SEQ ID NO: 8, 24, 14, 12, 22, and 10, and SEQ ID NO: 9, 13, 25, 23, 15, and 11, SEQ ID NO: 18, 26, 20, 4, 6, and 16, and SEQ ID NO: 7, 21, 17, 5, 27, and 19, SEQ ID NO: 22, 24, 12, 14, 8, and 10, and SEQ ID NO: 15, 25, 9, 23, 13, and 11, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 8, 30, 14, 12, 26, and 10, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 7, 21, 5, 25, 33, and 19, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 8, 30, 14, 12, 26, and 10,Array numbers 8, 30, 14, 12, 26, and 10, and array numbers 9, 13, 31, 27, 15, and 11, array numbers 6, 20, 4, 24, 32, and 18, and array numbers 8, 12, 30, 26, 14, and 10, array numbers 7, 21, 5, 25, 33, and 19, and array numbers 9, 13, 31, 27, 15, and 11, array numbers 20, 32, 24, 4, 6, and 18, and array numbers 26, 30, 12, 14, 8, and 10, array numbers 7, 25, 19, 5, 33, and 21, and array numbers 15, 31, 9, 27, 13, and 11, array numbers 24, 6, 16, and 18, and array numbers 26, 20, 10, and 28, array numbers 24, 6, 16, and 18, and array numbers 26, 10, 20, and 28, array numbers 24, 6, 16, and 18, and array numbers 7, 25, 17, and 19, array numbers 7, 19, 17, and 25, and array numbers 21, 27, 11, and 29, array numbers 24, 16, 6, and 18, and array numbers 27, 11, 21, and 29, array numbers 7, 25, 17, and 19, and array numbers 11, 27, 21, and 29, array numbers 7, 25, 17, and 19, and array numbers 21, 27, 11, and 29, array numbers 22, 6, 20, and 28, and array numbers 23, 7, 21, and 29, array numbers 22, 20, 6, and 28, and array numbers 7, 21, 23, and 29, array numbers 26, 10, 20, and 28, and array numbers 21, 27, 11, and 29, array numbers 22, 6, 16, 20, 18, 28, 26, and 10, or, array numbers 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, or any one amino acid sequence of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, and comprises a vector comprising one or more polynucleotides encoding one or more fusion polypeptides. In some embodiments,The immunogenic composition comprises one or more fusion polypeptides, or one or more polynucleotides encoding one or more fusion polypeptides, which contain or consist of an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223. In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding the following first and second fusion polypeptides, or the following first and second fusion polypeptides optionally linked or connected by one or more linkers, or one or more vectors or one or more lipidplexes (e.g., LNP): a fusion polypeptide that is SEQ ID NOs: 70 and 71, or any one of SEQ ID NOs: 70 and 71 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto; a fusion polypeptide that is SEQ ID NOs: 72 and 73, or any one of SEQ ID NOs: 72 and 73 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical thereto; a fusion polypeptide that is SEQ ID NOs: 74 and 75, or any one of SEQ ID NOs: 74 and 75 and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NOs: 78 and 79, or either one of SEQ ID NOs: 78 and 79, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 80 and 81, or either one of SEQ ID NOs: 80 and 81, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 82 and 83, or either one of SEQ ID NOs: 82 and 83, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 84 and 85, or either one of SEQ ID NOs: 84 and 85, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 86 and 87, or either one of SEQ ID NOs: 86 and 87, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 88 and 89, or either one of SEQ ID NOs: 88 and 89, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 82 and 85, or either one of SEQ ID NOs: 82 and 85, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 82 and 86,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 86, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 89, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 101,A fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 90 and 91, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88% respectively with either one of SEQ ID NO: 90 and 91 A fusion polypeptide that is 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 92 and 93, or either one of SEQ ID NOs: 92 and 93; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 94 and 95, or either one of SEQ ID NOs: 94 and 95; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 96 and 97, or either one of SEQ ID NOs: 96 and 97; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 94 and 96, or either one of SEQ ID NOs: 94 and 96; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 95 and 97, or either one of SEQ ID NOs: 95 and 97; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 220 and 221, or either one of SEQ ID NOs: 220 and 221; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to, SEQ ID NOs: 98 and 100, or either one of SEQ ID NOs: 98 and 100;A fusion polypeptide that is 98% or 99% identical, SEQ ID NO: 99 and 101, or either one of SEQ ID NO: 99 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, or SEQ ID NO: 100 and 101, or either one of SEQ ID NO: 100 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively. In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers in the order from the N-terminus to the C-terminus, the following first fusion polypeptide and second fusion polypeptide, or one or more vectors or one or more lipoplexes (e.g., LNP): SEQ ID NO: 70 and 71, or either one of SEQ ID NO: 70 and 71 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 71 and 70, or either one of SEQ ID NO: 71 and 70 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 72 and 73, or either one of SEQ ID NO: 72 and 73 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,A fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 73 and 72, or any one of SEQ ID NO: 73 and 72 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 74 and 75, or any one of SEQ ID NO: 74 and 75 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 75 and 74, or any one of SEQ ID NO: 75 and 74 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 76 and 77, or any one of SEQ ID NO: 76 and 77 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 77 and 76, or any one of SEQ ID NO: 77 and 76 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 78 and 79, or any one of SEQ ID NO: 78 and 79 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide, SEQ ID NO: 79 and 78, or any one of SEQ ID NO: 79 and 78 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide,A fusion polypeptide that is identical to SEQ ID NO: 80 and 81, or either one of SEQ ID NO: 80 and 81, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 81 and 80, or either one of SEQ ID NO: 81 and 80, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 82 and 83, or either one of SEQ ID NO: 82 and 83, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 83 and 82, or either one of SEQ ID NO: 83 and 82, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 84 and 85, or either one of SEQ ID NO: 84 and 85, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 85 and 84, or either one of SEQ ID NO: 85 and 84, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 86 and 87, or either one of SEQ ID NO: 86 and 87, and is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto respectively; a fusion polypeptide that is identical to SEQ ID NO: 87 and 86, or either one of SEQ ID NO: 87 and 86, and is at least 80%, 81%,A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 88 and 89, or either one of SEQ ID NOs: 88 and 89 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 89 and 88, or either one of SEQ ID NOs: 89 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 82 and 85, or either one of SEQ ID NOs: 82 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 85 and 82, or either one of SEQ ID NOs: 85 and 82 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 82 and 86, or either one of SEQ ID NOs: 82 and 86 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 86 and 82, or either one of SEQ ID NOs: 86 and 82 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 82 and 88, or either one of SEQ ID NOs: 82 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%,A fusion polypeptide that is 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 88 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92% identical to either SEQ ID NO: 88 and 82 respectively, A fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 83 and 87, or SEQ ID NO: 83 and 87, or any one of SEQ ID NO: 83 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 87 and 83, or SEQ ID NO: 87 and 83, or any one of SEQ ID NO: 87 and 83 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 87, or SEQ ID NO: 85 and 87, or any one of SEQ ID NO: 85 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 87 and 85, or SEQ ID NO: 87 and 85, or any one of SEQ ID NO: 87 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 88 and 87, or SEQ ID NO: 88 and 87, or any one of SEQ ID NO: 88 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 87 and 88, or SEQ ID NO: 87 and 88, or any one of SEQ ID NO: 87 and 88 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 84 and 88, or SEQ ID NO: 88 and 84, or any one of SEQ ID NO: 88 and 84 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, a fusion polypeptideA fusion polypeptide that is identical to SEQ ID NO: 88 and 84, or either one of SEQ ID NO: 88 and 84, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 85 and 89, or either one of SEQ ID NO: 85 and 89, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 89 and 85, or either one of SEQ ID NO: 89 and 85, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 85 and 101, or either one of SEQ ID NO: 85 and 101, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 101 and 85, or either one of SEQ ID NO: 101 and 85, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 90 and 91, or either one of SEQ ID NO: 90 and 91, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 91 and 90, or either one of SEQ ID NO: 91 and 90, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 92 and 93, or either one of SEQ ID NO: 92 and 93, respectively, by at least 80%,A fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 93 and 92, or either one of SEQ ID NO: 93 and 92 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 94 and 95, or either one of SEQ ID NO: 94 and 95 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 95 and 94, or either one of SEQ ID NO: 95 and 94 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 96 and 97, or either one of SEQ ID NO: 96 and 97 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 97 and 96, or either one of SEQ ID NO: 97 and 96 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 94 and 96, or either one of SEQ ID NO: 94 and 96 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 96 and 94, or either one of SEQ ID NO: 96 and 94 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,A fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 95 and 97, or any one of SEQ ID NO: 95 and 97 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is SEQ ID NO: 97 and 95, or any one of SEQ ID NO: 97 and 95 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is SEQ ID NO: 220 and 221, or any one of SEQ ID NO: 220 and 221 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is SEQ ID NO: 221 and 220, or any one of SEQ ID NO: 221 and 220 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is SEQ ID NO: 98 and 100, or any one of SEQ ID NO: 98 and 100 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is SEQ ID NO: 100 and 98, or any one of SEQ ID NO: 100 and 98 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is SEQ ID NO: 99 and 101, or any one of SEQ ID NO: 99 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NO: 101 and 99, or either one of SEQ ID NO: 101 and 99 and each at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, a fusion polypeptide that is SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99 and each at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, a fusion polypeptide that is SEQ ID NO: 99 and 98, or either one of SEQ ID NO: 99 and 98 and each at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, a fusion polypeptide that is SEQ ID NO: 100 and 101, or either one of SEQ ID NO: 100 and 101 and each at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, or a fusion polypeptide that is SEQ ID NO: 101 and 100, or either one of SEQ ID NO: 101 and 100 and each at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, the first and second polynucleotides, the first and second viral vectors, or the first and second lipoplexes (e.g., LNP) comprising: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 82 and 83, or either one of SEQ ID NO: 82 and 83 and each at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%,One or more polynucleotides encoding a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP), (b) a first fusion polypeptide comprising SEQ ID NOs: 86 and 87 and a second fusion polypeptide, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 86 or 87. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector, or a first and a second lipoplex (e.g., LNP), comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide that are optionally linked or connected by one or more linkers: (a) a first polynucleotide, or a first viral vector, or a first lipoplex (e.g., LNP), comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 84 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or 85; (b) a second polynucleotide, or a second viral vector, or a second lipoplex (e.g., LNP), comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 88 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 89.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, the first and second polynucleotides or the first and second viral vectors or the first and second lipoplexes (e.g., LNP) comprising: (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 86; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, and comprises a first and a second viral vector or a first and a second lipoplex (e.g., LNP): (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 85, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 85; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 87.In some embodiments, the immunogenic composition comprises first and second viral vectors or first and second lipoplexes (e.g., LNPs) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, wherein: (a) a first polynucleotide or first viral vector or first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or SEQ ID NO: 88; (b) a second polynucleotide or second viral vector or second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or SEQ ID NO: 87.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, the first and second polynucleotides or the first and second viral vectors or the first and second lipoplexes (e.g., LNP) comprising: (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or SEQ ID NO: 88; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 89, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or SEQ ID NO: 89.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, the first and second polynucleotides or the first and second viral vectors or the first and second lipoplexes (e.g., LNPs) comprising: (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or SEQ ID NO: 100; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 85 and 101, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or SEQ ID NO: 101. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NOs: 90 and 91, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 90 or SEQ ID NO: 91.In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 92 and 93, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 92 or 93. In some embodiments, the composition comprises a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers: (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 94 and 95, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 95, (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 96 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 96 or 97. In some embodiments, the immunogenic composition is optionally linked or connected by one or more linkers. One or more polynucleotides encoding the following first and second fusion polypeptides, comprising a first and second polynucleotide or a first and second viral vector or a first and second lipoplex (e.g., LNP): (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 96; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 95 or 97.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, the first and second polynucleotides or the first and second viral vectors or the first and second lipoplexes (e.g., LNPs) comprising: (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 220 and 221, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 220 and 221; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 95 and 97.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide optionally linked or connected by one or more linkers, the first and second polynucleotides or the first and second viral vectors or the first and second lipoplexes (e.g., LNP) comprising: (a) a first polynucleotide or a first viral vector or a first lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 98 and 100, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or 100; (b) a second polynucleotide or a second viral vector or a second lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 99 and 101, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 99 or 101. In some embodiments, the immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 82 and 85, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 85, optionally linked or connected by one or more linkers.In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, which are optionally linked or connected by one or more linkers and comprise SEQ ID NO: 82 and 88, or either SEQ ID NO: 82 or 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and comprises a viral vector or a lipoplex (e.g., LNP). In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, which are optionally linked or connected by one or more linkers and comprise SEQ ID NO: 85 and 87, or either SEQ ID NO: 85 or 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and comprises a viral vector or a lipoplex (e.g., LNP). In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, which are optionally linked or connected by one or more linkers and comprise SEQ ID NO: 87 and 88, or either SEQ ID NO: 87 or 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and comprises a viral vector or a lipoplex (e.g., LNP).In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides comprising a fusion polypeptide that is optionally linked or connected by one or more linkers and that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 94 and 95, or either of SEQ ID NO: 94 and 95. The immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP). In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides comprising a fusion polypeptide that is optionally linked or connected by one or more linkers and that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 96 and 97, or either of SEQ ID NO: 96 and 97. The immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP). In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides comprising a fusion polypeptide that is optionally linked or connected by one or more linkers and that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 98 and 99, or either of SEQ ID NO: 98 and 99. The immunogenic composition comprises a viral vector or a lipoplex (e.g., LNP).In some embodiments, the immunogenic composition comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide, the first and second fusion polypeptides comprising a fusion polypeptide linked or connected, optionally by one or more linkers, of SEQ ID NO: 100 and 101, or any one of SEQ ID NO: 100 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, and comprises a viral vector or a lipoplex (e.g., LNP). In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polynucleotide encoding a polypeptide comprising SEQ ID NO: 200, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 200, and a second viral vector or lipoplex (e.g., LNP) comprising a second polynucleotide encoding a polypeptide comprising SEQ ID NO: 201, or a polypeptide at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201.In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polypeptide comprising SEQ ID NO: 202, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, and a second viral vector or lipoplex (e.g., LNP) comprising a second polypeptide comprising SEQ ID NO: 203, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a first polypeptide comprising SEQ ID NO: 203, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203, and a second viral vector or lipoplex (e.g. For example, it includes a first viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 105, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105, and a second viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 107, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 206, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 206, and a second viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 207, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 207. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 208, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 208, and a secondA second viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 222, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the immunogenic composition comprises a first viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 222, or a first polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, and a second viral vector or lipoplex (e.g., LNP) comprising a polypeptide comprising SEQ ID NO: 223, or a second polynucleotide encoding a polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223.It includes. In some embodiments, the immunogenic composition comprises any one nucleic acid sequence of SEQ ID NOs: 130-167, 210-219, and 225-226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or comprises a polynucleotide consisting of these. In some embodiments, the immunogenic composition comprises any one nucleic acid sequence of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or comprises a polynucleotide consisting of these. In some embodiments, the immunogenic composition comprises the following first polynucleotide and second polynucleotide, or one or more vectors comprising the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NOs: 130 and 132, SEQ ID NOs: 130 and 134, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NOs: 130 and 134, SEQ ID NOs: 131 and 133, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,Polynucleotides that are 96%, 97%, 98% or 99% identical, SEQ ID NOs: 131 and 135, or either one of SEQ ID NOs: 131 and 135 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 132 and 136, or either one of SEQ ID NOs: 132 and 136 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 133 and 135, or either one of SEQ ID NOs: 133 and 135 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 133 and 137, or either one of SEQ ID NOs: 133 and 137 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 134 and 136, or either one of SEQ ID NOs: 134 and 136 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 135 and 137, or either one of SEQ ID NOs: 135 and 137 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 138 and 141, or either one of SEQ ID NOs: 138 and 141 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NO: 138 and 144, or either one of SEQ ID NO: 138 and 144 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 139 and 142, or either one of SEQ ID NO: 139 and 142 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 139 and 145, or either one of SEQ ID NO: 139 and 145 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 140 and 146, or either one of SEQ ID NO: 140 and 146 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 142 and 148, or either one of SEQ ID NO: 142 and 148 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 143 and 149, or either one of SEQ ID NO: 143 and 149 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 145 and 148, or either one of SEQ ID NO: 145 and 148 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A polynucleotide that is 98% or 99% identical, SEQ ID NO: 150 and 152, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 150 or 152 and each polynucleotide, SEQ ID A polynucleotide that is identical to SEQ ID NO: 150 and 155, or either one of SEQ ID NO: 150 and 155, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 151 and 153, or either one of SEQ ID NO: 151 and 153, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 151 and 156, or either one of SEQ ID NO: 151 and 156, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 152 and 158, or either one of SEQ ID NO: 152 and 158, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 153 and 159, or either one of SEQ ID NO: 153 and 159, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 154 and 157, or either one of SEQ ID NO: 154 and 157, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 155 and 158, or either one of SEQ ID NO: 155 and 158, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a polynucleotide that is identical to SEQ ID NO: 156 and 159,or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 156 and 159, SEQ ID NOs: 160 and 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 160 and 161, SEQ ID NOs: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 162 and 163, SEQ ID NOs: 164 and 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 164 and 165, SEQ ID NOs: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 166 and 167, SEQ ID NOs: 210 and 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 210 and 211, SEQ ID NOs: 212 and 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 212 and 213, SEQ ID NOs: 214 and 215or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 214 or 215, SEQ ID NO: 216 and 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 216 or 217, SEQ ID NO: 218 and 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 218 or 219, SEQ ID NO: 218 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 218 or 226, or SEQ ID NO: 225 and 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 225 or 226. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, a first and a second viral vector, or a first and a second lipoplex (e.g., LNP) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or a first lipoplex (e.g., LNP) comprising a first and a second polynucleotide comprising SEQ ID NO: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 131 or 135,(b) A second vector or a second lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 133 or SEQ ID NO: 137. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector, or a first and a second lipoplex (e.g., LNP) comprising the following first and second polynucleotides: (a) A first vector or a first lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 139 or SEQ ID NO: 145, (b) A second vector or a second lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 142 or SEQ ID NO: 148. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector, or a first and a second lipoplex (e.g., LNP) comprising the following first and second polynucleotides: (a) A first vector or a first lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 140 or SEQ ID NO: 146,(b) A second vector or second lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 143 or SEQ ID NO: 149. In some embodiments, the first and second viral vectors of such an immunogenic composition are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors. In some embodiments, the immunogenic composition comprises a first and second polynucleotide or first and second viral vector or first and second lipoplex (e.g., LNP) comprising the following first polynucleotide and second polynucleotide: (a) a first vector or first lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 150 or SEQ ID NO: 152, (b) a second vector or second lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NOs: 154 and 157 or SEQ ID NOs: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158. In some embodiments, the first and second viral vectors of such an immunogenic composition are Calomyscamine mammarenavirus (alternatively, Pichinde mammarenavirus or Pichinde arenavirus) viral vectors. In some embodiments, the immunogenic composition comprises the following first polynucleotide and second polynucleotide,Comprising a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP): (a) a first and a second polynucleotide comprising SEQ ID NO: 151 and 153, or any one of SEQ ID NO: 151 and 153 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% respectively, A first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 156, or a polynucleotide comprising SEQ ID NOs: 156 and 159, or either SEQ ID NO: 156 or 159 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; and a second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 159, or a polynucleotide comprising SEQ ID NOs: 156 and 159, or either SEQ ID NO: 156 or 159 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide, or a first and a second viral vector, or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 160, or a first viral vector or first lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 160; (b) a polynucleotide of SEQ ID NO: 161, or a second viral vector or second lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 161.In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 162, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 162, in a first viral vector or a first lipoplex (e.g., LNP), (b) a polynucleotide of SEQ ID NO: 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 163, in a second viral vector or a second lipoplex (e.g., LNP). In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 164, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 164, in a first viral vector or a first lipoplex (e.g., LNP), (b) a polynucleotide of SEQ ID NO: 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 165, in a second viral vector or a second lipoplex (e.g., LNP).In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 166, or a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 166 respectively; (b) a polynucleotide of SEQ ID NO: 167, or a second viral vector or a second lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 167 respectively. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a polynucleotide of SEQ ID NO: 210, or a first viral vector or a first lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210; (b) a polynucleotide of SEQ ID NO: 211, or a second viral vector or a second lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211.In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212, (b) a second viral vector or a second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214, (b) a second viral vector or a second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215.In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216, (b) a second viral vector or a second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, (b) a second viral vector or a second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219.In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218, (b) a second viral vector or a second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises a first and a second polynucleotide or a first and a second viral vector or a first and a second lipoplex (e.g., LNP) comprising one or more polynucleotides: (a) a first viral vector or a first lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225, (b) a second viral vector or a second lipoplex (e.g., LNP) comprising the polynucleotide of SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the immunogenic composition comprises a complex fusion polypeptide and a vector or lipoplex comprising a polynucleotide encoding the complex fusion polypeptide. comprises a complex fusion polypeptide and a vector or lipoplex (e.g., LNP) encoding the complex fusion polypeptide, and the complex fusion polypeptide comprises any one of the amino acid sequences of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or consists of these. In some embodiments, the immunogenic composition comprises a complex fusion polypeptide and a vector or lipoplex (e.g., LNP) encoding the complex fusion polypeptide, and the complex fusion polypeptide comprises any one of the amino acid sequences of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223, or consists of these. In some embodiments, one or more fusion polypeptides do not comprise any polypeptide segment corresponding to Gag 54-146, Gag 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, wherein the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, one or more fusion polypeptides do not comprise a polypeptide segment having the amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof.In various embodiments of the immunogenic composition, the first and second viral vectors can be lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Calymmamyovirus (also known as Pichinde mammarenavirus or Pichinde arenavirus) viral vectors, or adenoviral vectors, such as chimpanzee adenoviral vectors (ChAds). In some embodiments, the immunogenic composition comprises a single vector comprising one or more polynucleotides encoding the first and second fusion polypeptides. In some embodiments, the immunogenic composition further comprises one or more of an adjuvant, a detergent, a micelle-forming agent, and an oil. In some embodiments, the immunogenic composition is formulated for administration via a route selected from intravenous, intramuscular, intradermal, subcutaneous, intranodular, and intramucosal (e.g., buccal, intranasal, rectal, vaginal). In some embodiments, the immunogenic composition is formulated as a liquid, suspension, or emulsion. In some embodiments, the immunogenic composition is lyophilized.

[0015] There is further provided a kit comprising one or more unit doses of one or more of the fusion polypeptides, one or more of the complex fusion polypeptides, one or more of the polynucleotides, one or more of the vectors, or one or more of the immunogenic compositions described herein. In some embodiments, the kit comprises two or more of the fusion polypeptides described herein, two or more of the complex fusion polypeptides, two or more of the polynucleotides, two or more of the vectors, or two or more of the immunogenic compositions. In some embodiments, the one or more unit doses are in a single container. In some embodiments, the one or more unit doses are in two or more separate containers. In some embodiments, the kit comprises one or more containers selected from vials, ampoules, and pre-filled syringes. In some embodiments, the kit comprises one or more containers containing one or more of the fusion polypeptides, one or more of the polynucleotides, or one or more of the vectors in an aqueous solution. In some embodiments, the one or more unit doses are the same. In some embodiments, the one or more unit doses are different. In some embodiments, the kit comprises one or more unit doses of one or more viral vectors, and the unit dose is about 10 3 ~ about 10 12 viral focus forming units (FFU) or plaque forming units (PFU) or infectious units (IU) or viral particles (vp), e.g., about 10 4 ~ about 10 7 viral FFU or PFU or IU or vp, e.g., about 10 3 ~ about 10 4 , 10 5 , 10 6 , 10 7 , 10 8 , 10 9 , 10 10 , 10 11 , 10 12 , 10 13 , 10 14 or 10 15It is within the range of viral FFU or PFU or IU or vp. In some embodiments, the kit comprises a first fusion polypeptide and a second fusion polypeptide, or one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, wherein the first and second polypeptides comprise the following polypeptide segments linked or connected, optionally by one or more linkers, in order from the N-terminus to the C-terminus: SEQ ID NO: 6, 4, 16, and 26, and SEQ ID NO: 7, 5, 27, and 17, SEQ ID NO: 12, 24, 8, and 10, and SEQ ID NO: 9, 25, 13, and 11, SEQ ID NO: 14, 22, 18, 24, and 20, and SEQ ID NO: 15, 25, 19, 23, and 21, SEQ ID NO: 26, 16, 4, and 6, and SEQ ID NO: 7, 27, 5, and 17, SEQ ID NO: 8, 24, 12, and 10, and SEQ ID NO: 13, 25, 9, and 11, SEQ ID NO: 22, 24, 14, 18, and 20, and SEQ ID NO: 25, 23, 15, 21, and 19, SEQ ID NO: 20, 6, 4, 18, 16, and 26, and SEQ ID NO: 7, 19, 5, 21, 27, and 17, SEQ ID NO: 8, 24, 14, 12, 22, and 10, and SEQ ID NO: 9, 13, 25, 23, 15, and 11, SEQ ID NO: 18, 26, 20, 4, 6, and 16, and SEQ ID NO: 7, 21, 17, 5, 27, and 19, SEQ ID NO: 22, 24, 12, 14, 8, and 10, and SEQ ID NO: 15, 25, 9, 23, 13, and 11, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 8, 30, 14, 12, 26, and 10, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 7, 21, 5, 25, 33, and 19, SEQ ID NO: 24, 6, 4, 20, 18, and 32, and SEQ ID NO: 8, 30, 14, 12, 26, and 10, SEQ ID NO: 8, 30, 14, 12, 26, and 10, and SEQ ID NO: 9, 13, 31, 27, 15, and 11, SEQ ID NO: 6, 20, 4, 24, 32, and 18, and SEQ ID NO: 8, 12, 30, 26, 14, and 10, SEQ ID NO: 7, 21, 5, 25, 33, and 19, and SEQ ID NO: 9, 13, 31, 27, 15, and 11, SEQ ID NO: 20, 32, 24, 4, 6, and 18, and SEQ ID NO: 26, 30, 12, 14, 8, and 10, SEQ ID NO: 7, 25, 19, 5, 33, and 21, and SEQ ID NO: 15, 31, 9, 27, 13,and 11, SEQ ID NO: 24, 6, 16, and 18, and SEQ ID NO: 26, 20, 10, and 28, SEQ ID NO: 24, 6, 16, and 18, and SEQ ID NO: 26, 10, 20, and 28, SEQ ID NO: 24, 6, 16, and 18, and SEQ ID NO: 7, 25, 17, and 19, SEQ ID NO: 7, 19, 17, and 25, and SEQ ID NO: 21, 27, 11, and 29, SEQ ID NO: 24, 16, 6, and 18, and SEQ ID NO: 27, 11, 21, and 29, SEQ ID NO: 7, 25, 17, and 19, and SEQ ID NO: 11, 27, 21, and 29, SEQ ID NO: 7, 25, 17, and 19, and SEQ ID NO: 21, 27, 11, and 29, SEQ ID NO: 22, 6, 20, and 28, and SEQ ID NO: 23, 7, 21, and 29, SEQ ID NO: 22, 20, 6, and 28, and SEQ ID NO: 7, 21, 23, and 29, SEQ ID NO: 26, 10, 20, and 28, and SEQ ID NO: 21, 27, 11, and 29, SEQ ID NO: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NO: 7, 21, 19, 17, 27, 25, 29 and 11. In some embodiments, the kit comprises one or more fusion polypeptides, any one amino acid sequence of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or one or more fusion polypeptides encoding one or more amino acid sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, and comprises one or more vectors or one or more lipoplexes (LNPs) containing the above. In some embodiments, the immunogenic composition comprises one or more fusion polypeptides, any one amino acid sequence of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or one or more amino acid sequences that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, andOne or more vectors or one or more lipid nanoparticles (LNPs) comprising one or more polynucleotides encoding one or more fusion polypeptides, or consisting of these. In some embodiments, the kit comprises one or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, or the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: SEQ ID NO: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NO: 70 and 71; SEQ ID NO: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NO: 72 and 73; SEQ ID NO: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NO: 74 and 75; SEQ ID NO: 76 and 77, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NO: 76 and 77; SEQ ID NO: 78 and 79, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NO: 78 and 79; SEQ ID NO: 80 and 81, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%,A fusion polypeptide that is 96%, 97%, 98% or 99% identical, SEQ ID NO: 82 and 83, or any one of SEQ ID NO: 82 and 83 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 84 and 85, or any one of SEQ ID NO: 84 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 86 and 87, or any one of SEQ ID NO: 86 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 88 and 89, or any one of SEQ ID NO: 88 and 89 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 85, or any one of SEQ ID NO: 82 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 86, or any one of SEQ ID NO: 82 and 86 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 88, or any one of SEQ ID NO: 82 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 83 and 87,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87, SEQ ID NO: 85 and 87, or either SEQ ID NO: 85 or 87; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 87, SEQ ID NO: 88 and 87, or either SEQ ID NO: 88 or 87; SEQ ID NO: 88 and 87, or either SEQ ID NO: 88 or 87 and each is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92, A fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 84 and 88, or any one of SEQ ID NO: 84 and 88 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 89, or any one of SEQ ID NO: 85 and 89 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 101, or any one of SEQ ID NO: 85 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 90 and 91, or any one of SEQ ID NO: 90 and 91 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 92 and 93, or any one of SEQ ID NO: 92 and 93 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 94 and 95, or any one of SEQ ID NO: 94 and 95 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptide that is 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 96 and 97, or any one of SEQ ID NO: 96 and 97 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively; a fusion polypeptideA fusion polypeptide that is identical to SEQ ID NO: 94 and 96, or either one of SEQ ID NO: 94 and 96 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is identical to SEQ ID NO: 95 and 97, or either one of SEQ ID NO: 95 and 97 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is identical to SEQ ID NO: 220 and 221, or either one of SEQ ID NO: 220 and 221 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is identical to SEQ ID NO: 98 and 100, or either one of SEQ ID NO: 98 and 100 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is identical to SEQ ID NO: 99 and 101, or either one of SEQ ID NO: 99 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is identical to SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; or a fusion polypeptide that is identical to SEQ ID NO: 100 and 101, or either one of SEQ ID NO: 100 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto. In some embodiments, the kit comprisesOne or more vectors comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers in the order from the N-terminus to the C-terminus, or one or more lipoplexes (e.g., LNP): SEQ ID NO: 70 and 71, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 70 or 71 respectively; SEQ ID NO: 71 and 70, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 71 or 70 respectively; SEQ ID NO: 72 and 73, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 72 or 73 respectively; SEQ ID NO: 73 and 72, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 73 or 72 respectively; SEQ ID NO: 74 and 75, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 74 or 75 respectively; SEQ ID NO: 75 and 74, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 75 or 74 respectively; SEQ ID NO: 76 and 77,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 76 or 77, SEQ ID NO: 77 and 76, or either SEQ ID NO: 77 or 76; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 78 or 79, SEQ ID NO: 79 and 78, or either SEQ ID NO: 79 or 78; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 80 or 81, SEQ ID NO: 81 and 80, or either SEQ ID NO: 81 or 80; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 83, SEQ ID NO: 83 and 82, or either SEQ ID NO: 83 or 82;A fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 84 and 85, or either one of SEQ ID NOs: 84 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 85 and 84, or either one of SEQ ID NOs: 85 and 84 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 86 and 87, or either one of SEQ ID NOs: 86 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 87 and 86, or either one of SEQ ID NOs: 87 and 86 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 88 and 89, or either one of SEQ ID NOs: 88 and 89 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 89 and 88, or either one of SEQ ID NOs: 89 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%,A fusion polypeptide that is 97%, 98% or 99% identical, SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 85 and 82, The fusion polypeptide, SEQ ID NO: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 and 86 respectively, the fusion polypeptide, SEQ ID NO: 86 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 86 and 82 respectively, the fusion polypeptide, SEQ ID NO: 82 and 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 and 88 respectively, the fusion polypeptide, SEQ ID NO: 88 and 82, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 and 82 respectively, the fusion polypeptide, SEQ ID NO: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 and 87 respectively, the fusion polypeptide, SEQ ID NO: 87 and 83, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 87 and 83 respectively, the fusion polypeptide, SEQ ID NO: 85 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 and 87 respectively, the fusion polypeptide, SEQ ID NO: 87 and 85,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 87 or SEQ ID NO: 85, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or SEQ ID NO: 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 87 or SEQ ID NO: 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or SEQ ID NO: 88, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or SEQ ID NO: 84, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or SEQ ID NO: 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 89 or SEQ ID NO: 85, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or SEQ ID NO: 101, orA fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 101 and 85, or any one of SEQ ID NO: 101 and 85 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, SEQ ID NO: 90 and 91, or any one of SEQ ID NO: 90 and 91 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, SEQ ID NO: 91 and 90, or any one of SEQ ID NO: 91 and 90 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, SEQ ID NO: 92 and 93, or any one of SEQ ID NO: 92 and 93 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, SEQ ID NO: 93 and 92, or any one of SEQ ID NO: 93 and 92 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, SEQ ID NO: 94 and 95, or any one of SEQ ID NO: 94 and 95 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical fusion polypeptide, SEQ ID NO: 95 and 94, or any one of SEQ ID NO: 95 and 94 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%,A fusion polypeptide that is 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 96 and 97, or either one of SEQ ID NO: 96 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 97 and 96, or either one of SEQ ID NO: 97 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 94 and 96, or either one of SEQ ID NO: 94 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 96 and 94, or either one of SEQ ID NO: 96 and 94 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 95 and 97, or either one of SEQ ID NO: 95 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 97 and 95, or either one of SEQ ID NO: 97 and 95 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 220 and 221, or either one of SEQ ID NO: 220 and 221 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively,A fusion polypeptide that is identical to SEQ ID NO: 221 and 220, or either one of SEQ ID NO: 221 and 220, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 98 and 100, or either one of SEQ ID NO: 98 and 100, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 100 and 98, or either one of SEQ ID NO: 100 and 98, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 99 and 101, or either one of SEQ ID NO: 99 and 101, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 101 and 99, or either one of SEQ ID NO: 101 and 99, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; a fusion polypeptide that is identical to SEQ ID NO: 99 and 98, or either one of SEQ ID NO: 99 and 98, respectively, by at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99%; SEQ ID NO: 100 and 101,Or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 100 and 101, or, SEQ ID NO: 101 and 100, or either one of SEQ ID NO: 101 and 100 and at least 80%, 81% A fusion polypeptide that is 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the kit optionally comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide linked or connected by one or more linkers, and comprises a first, second, third, and fourth viral vector or lipoplex (e.g., LNP): (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 83, or any one of SEQ ID NOs: 82 and 83 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, respectively, (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 85, or any one of SEQ ID NOs: 84 and 85 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, respectively, (c) a third viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 86 and 87, or any one of SEQ ID NOs: 86 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, respectively, (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 88 and 89, or any one of SEQ ID NOs: 88 and 89 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%,A fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical. In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide that are linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 82 and 86, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 86, (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 83 and 87, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87. In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide that are linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 82 and 85, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 85,The first viral vector or lipoplex (e.g., LNP), (b) the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NO: 88 and 87, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 87, respectively. In some embodiments, the kit optionally comprises the first and second viral vectors or lipoplexes (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide linked or connected by one or more linkers: (a) the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NO: 82 and 88, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 88, respectively, of the first viral vector or lipoplex (e.g., LNP), (b) the first fusion polypeptide and the second fusion polypeptide comprising SEQ ID NO: 85 and 87, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 87, respectively, of the second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises the first and second viral vectors or lipoplexes (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide linked or connected by one or more linkers: (a) the fusion polypeptide comprising SEQ ID NO: 200, or at least 80%, 81%, 82%, 83%,A first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; (b) a fusion polypeptide comprising SEQ ID NO: 201, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 201, a second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers, a first and second viral vector or lipoplex (e.g., LNP) comprising: (a) a fusion polypeptide comprising SEQ ID NO: 202, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 202, a first viral vector or lipoplex (e.g., LNP); (b) a fusion polypeptide comprising SEQ ID NO: 203, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 203, a second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers, a first and second viral vector or lipoplex (e.g., LNP) comprising: (a) a fusion polypeptide comprising SEQ ID NO: 204, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%,A first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; (b) a fusion polypeptide comprising SEQ ID NO: 205, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 205, a second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 105 or 206, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 105 or 206 respectively, a first viral vector or lipoplex (e.g., LNP); (b) a fusion polypeptide comprising SEQ ID NO: 107 or 207, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 107 or 207 respectively, a second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first and second fusion polypeptides linked or connected by one or more linkers: (a) a fusion polypeptide comprising SEQ ID NO: 208, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%,A first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide that is 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, (b) SEQ ID NO: 209 if, A second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222, (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 209 or SEQ ID NO: 227, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 209 or SEQ ID NO: 227. In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding a fusion polypeptide comprising SEQ ID NO: 222, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 222,The first viral vector or lipoplex (e.g., LNP), (b) a fusion polypeptide comprising SEQ ID NO: 223, or a polynucleotide encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 223. In some embodiments, the kit optionally comprises one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide linked or connected by one or more linkers, the first, second, third, and fourth viral vectors or lipoplexes (e.g., LNP) comprising: (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 82 and 86, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or SEQ ID NO: 86, respectively, (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 83 and 87, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or SEQ ID NO: 87, respectively, (c) a third viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 84 and 88, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or SEQ ID NO: 88, respectively, (e.g.,A fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 85 and 89, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 89. In some embodiments, the kit optionally comprises a first, second, third, and fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide that are linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 82 and 86, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 86, (b) a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 83 and 87, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87, (c) a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 98 and 100, or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or 100,A third viral vector or lipoplex (e.g., LNP), (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 85 and 101, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 85 or 101, respectively. In some embodiments, the kit optionally comprises a first, second, third, and fourth viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide that are linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 82 and 86, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 86, respectively; (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 83 and 87, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87, respectively; (c) a third viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 98 and 100, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,One or more polynucleotides encoding a fusion polypeptide that is 98% or 99% identical, a third viral vector or lipoplex (e.g., LNP), (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 99 and 101, or any one of SEQ ID NOs: 99 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, respectively, a fourth viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide linked or connected by one or more linkers: (a) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 90 and 91, or any one of SEQ ID NOs: 90 and 91 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, respectively, a first viral vector or lipoplex (e.g., LNP), (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 92 and 93, or any one of SEQ ID NOs: 92 and 93 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto, respectively, a second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit optionally comprises a first and a second viral vector or lipoplex (e.g.,comprising an LNP): (a) the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NO: 94 and 96, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 96, (a) a first viral vector or lipoplex (e.g., LNP), (b) the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NO: 95 and 97, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 95 or 97, respectively, of a second viral vector or lipoplex (e.g., LNP). In some embodiments, the kit comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NO: 220 and 221, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 220 or 221, respectively, (b) a second viral vector or lipoplex (e.g., LNP) comprising the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NO: 95 and 97, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 95 or 97, respectively. In some embodiments, the kit comprises a first and a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers: (a) the following first fusion polypeptide and second fusion polypeptide comprising SEQ ID NO: 94 and 95,a first viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 95; (b) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 96 and 97, or a second viral vector or lipoplex (e.g., LNP) comprising one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 96 or 97. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNP) comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide that are optionally linked or connected by one or more linkers: (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 98 and 100, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or 100; (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NO: 99 and 101, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 99 or 101. In some embodiments, the kit isOne or more polynucleotides encoding the following first and second fusion polypeptides optionally linked or connected by one or more linkers, comprising first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs): (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 96, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 96; (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 95 and 97, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 95 or 97; (c) a third viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 100, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or 100; (d) a fourth viral vector or lipoplex (e.g.,LNP). In some embodiments, the kit optionally comprises one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide linked or connected by one or more linkers, and first, second, third, and fourth viral vectors or lipoplexes (e.g., LNP) comprising: (a) a first viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 94 and 95, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 94 or 95; (b) a second viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 96 and 97, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 96 or 97; (c) a third viral vector or lipoplex (e.g., LNP) comprising a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 98 and 99, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 98 or 99; (d) a first fusion polypeptide and a second fusion polypeptide comprising SEQ ID NOs: 100 and 101, or one or more polynucleotides encoding a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 100 or 101,A fourth viral vector or lipoplex (e.g., LNP). In various embodiments of the kit, the first and second viral vectors are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors, Calymmamyovirus (also known as Pichinde mammarenavirus or Pichinde arenavirus) viral vectors, or adenoviral vectors, e.g., chimpanzee adenoviral vectors (ChAds). In some embodiments, the kit comprises a nucleic acid sequence of any one of SEQ ID NOs: 130-167, 210-219, and 225-226, or a polynucleotide comprising or consisting of a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 130-167, 210-219, and 225-226. In some embodiments, the kit comprises a nucleic acid sequence of any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226, or a polynucleotide comprising or consisting of a nucleic acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 139, 140, 142, 143, 145, 146, 148, 149, 150, 152, 155, 158, 225, and 226. In some embodiments, the kit comprises one or more vectors or one or more lipoplexes (e.g., LNP) comprising the following first polynucleotide and second polynucleotide, the following first polynucleotide and second polynucleotide: SEQ ID NOs: 130 and 132, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to each of SEQ ID NOs: 130 and 132, SEQ ID NOs: 130 and 134, or polynucleotides that are at least 80%, 81%,Polynucleotides that are 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 131 and 133, or at least 80%, 81%, 82%, 83%, 84%, 85%, 8, Polynucleotides that are 6%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 131 and 135, or either one of SEQ ID NOs: 131 and 135 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 132 and 136, or either one of SEQ ID NOs: 132 and 136 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 133 and 135, or either one of SEQ ID NOs: 133 and 135 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 133 and 137, or either one of SEQ ID NOs: 133 and 137 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 134 and 136, or either one of SEQ ID NOs: 134 and 136 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 135 and 137, or either one of SEQ ID NOs: 135 and 137 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 138 and 141, or either one of SEQ ID NOs: 138 and 141 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%,Polynucleotides that are 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 138 and 144, or either one of SEQ ID NOs: 138 and 144 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 139 and 142, or either one of SEQ ID NOs: 139 and 142 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 139 and 145, or either one of SEQ ID NOs: 139 and 145 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 140 and 146, or either one of SEQ ID NOs: 140 and 146 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 142 and 148, or either one of SEQ ID NOs: 142 and 148 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 143 and 149, or either one of SEQ ID NOs: 143 and 149 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NOs: 145 and 148, or either one of SEQ ID NOs: 145 and 148 and polynucleotides that are respectively at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%,Polynucleotides that are 96%, 97%, 98% or 99% identical, SEQ ID NOs: 150 and 152, or either one of SEQ ID NOs: 150 and 152 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 150 and 155, or either one of SEQ ID NOs: 150 and 155 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 151 and 153, or either one of SEQ ID NOs: 151 and 153 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 151 and 156, or either one of SEQ ID NOs: 151 and 156 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 152 and 158, or either one of SEQ ID NOs: 152 and 158 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 153 and 159, or either one of SEQ ID NOs: 153 and 159 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 154 and 157, or either one of SEQ ID NOs: 154 and 157 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,Polynucleotides that are 98% or 99% identical, SEQ ID NOs: 155 and 158, or either one of SEQ ID NOs: 155 and 158 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 156 and 159, or either one of SEQ ID NOs: 156 and 159 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 160 and 161, or either one of SEQ ID NOs: 160 and 161 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 162 and 163, or either one of SEQ ID NOs: 162 and 163 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 164 and 165, or either one of SEQ ID NOs: 164 and 165 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 166 and 167, or either one of SEQ ID NOs: 166 and 167 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 210 and 211, or either one of SEQ ID NOs: 210 and 211 and polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A polynucleotide that is 98% or 99% identical, SEQ ID NOs: 212 and 213, or either one of SEQ ID NOs: 212 and 213 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 214 and 215, or either one of SEQ ID NOs: 214 and 215 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 216 and 217, or either one of SEQ ID NOs: 216 and 217 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 218 and 219, or either one of SEQ ID NOs: 218 and 219 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NOs: 218 and 226, or either one of SEQ ID NOs: 218 and 226 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, or SEQ ID NOs: 225 and 226, or either one of SEQ ID NOs: 225 and 226 and a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively. In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNP) comprising the following first polynucleotide and second polynucleotide: (a) first and second polynucleotides comprising SEQ ID NOs: 131 and 135,or a first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either of SEQ ID NOs: 131 and 135, (b) first and second, arr, A polynucleotide containing column numbers 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 133 and 137, a second vector or lipoplex (e.g., LNP). In some embodiments, the kit comprises a first and a second viral vector or lipoplex (e.g., LNP) containing the following first polynucleotide and second polynucleotide: (a) a first vector or lipoplex (e.g., LNP) containing a first and a second polynucleotide containing SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 139 and 145; (b) a second vector or lipoplex (e.g., LNP) containing a first and a second polynucleotide containing SEQ ID NOs: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NOs: 139 and 145.In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), and each vector or lipoplex (e.g., LNP) comprises first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 131 and 135, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 131 or 135; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 133 and 137, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 133 or 137; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 139 and 145, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 139 or 145; (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NOs: 142 and 148, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 142 or 148.In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 140 and 146, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 140 or 146; (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 143 and 149, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 143 or 149. In some embodiments, the first and second viral vectors are lymphocytic choriomeningitis mammarenavirus (LCMV) viral vectors.In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 150 or 152; (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158. In some embodiments, the first and second viral vectors are Calimana marena virus (also known as Pichinde marena virus or Pichinde arenavirus) viral vectors.In some embodiments, the kit includes first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), and each vector or lipoplex (e.g., LNP) includes first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) including first and second polynucleotides comprising SEQ ID NO: 140 and 146, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 140 or 146 respectively; (b) a second viral vector or lipoplex (e.g., LNP) including first and second polynucleotides comprising SEQ ID NO: 143 and 149, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 143 or 149 respectively; (c) a third viral vector or lipoplex (e.g., LNP) including first and second polynucleotides comprising SEQ ID NO: 150 and 152, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 150 or 152 respectively; (d) a fourth viral vector or lipoplex (e.g., LNP) including first and second polynucleotides comprising SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158, or polynucleotides that are at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 154 and 157 or SEQ ID NO: 155 and 158 respectively.In some embodiments, the kit comprises first, second, third, and fourth viral vectors or lipoplexes (e.g., LNPs), wherein each vector or lipoplex (e.g., LNP) comprises first and second polynucleotides: (a) a first viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 150 and 152, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NO: 150 or 152; (b) a second viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 155 and 158, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NO: 155 or 158; (c) a third viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 151 and 153, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NO: 151 or 153; (d) a fourth viral vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 156 and 159, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to either SEQ ID NO: 156 or 159. In various embodiments, one or more of the first, second, third, and fourth vectors are adenoviral vectors.In some embodiments, the kit comprises first and second viral vectors or lipoplexes (e.g., LNPs) comprising the following first and second polynucleotides: (a) a first vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 160 and 161, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 160 or 161; (b) a second vector or lipoplex (e.g., LNP) comprising first and second polynucleotides comprising SEQ ID NO: 162 and 163, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 162 or 163. In some embodiments, the kit comprises first and second viral vectors comprising the following first and second polynucleotides: (a) first and second polynucleotides comprising SEQ ID NO: 164 and 165, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86... A first vector or lipoplex (e.g., LNP) comprising a polynucleotide that is 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical; (b) a polynucleotide comprising the first and second polynucleotides of SEQ ID NO: 166 and 167, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 166 or 167, a second vector or lipoplex (e.g., LNP). In some embodiments, the kit comprises: (a) a first polynucleotide comprising SEQ ID NO: 210, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 210, a first viral vector or lipoplex (e.g., LNP); and (b) a second polynucleotide comprising SEQ ID NO: 211, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 211, a second viral vector or lipoplex (e.g., LNP).In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 212, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 212; and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 213, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 213. In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 214, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 214; and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 215, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 215.In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 216, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 216; and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 217, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 217. In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 219, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 219.In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 218, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 218; and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226. In some embodiments, the kit comprises: (a) a first viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 225, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 225; and (b) a second viral vector or lipoplex (e.g., LNP) comprising a polynucleotide comprising SEQ ID NO: 226, or a polynucleotide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 226.In some embodiments, the kit comprises a composite fusion polypeptide and a vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 105-112, 200-209, 222-223, and 227, or consists of these. In some embodiments, the kit comprises a composite fusion polypeptide and a vector or lipoplex (e.g., LNP) comprising a polynucleotide encoding the composite fusion polypeptide, wherein the composite fusion polypeptide comprises the amino acid sequence of any one of SEQ ID NOs: 209, 222, and 223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 209, 222, and 223, or consists of these. In some embodiments, one or more fusion polypeptides are Gag 54-146, Gag. Does not include any polypeptide segments corresponding to 370-500, Pol 1-55, Pol 118-128, Pol 321-366, Pol 432-541, Pol 607-682, Pol 709-746, Pol 828-839, Pol 921-931, Nef 1-63, Nef 100-116, and Nef 149-206, or fragments or subsequences thereof, where the amino acid position numbers of Gag, Pol, and Nef correspond to SEQ ID NOs: 1, 2, and 3, respectively. In some embodiments, one or more fusion polypeptides do not include polypeptide segments having an amino acid sequence of SEQ ID NOs: 35-47, or fragments or subsequences thereof, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 35-47, or fragments or subsequences thereof. In some embodiments, the kit further includes one or more additional therapeutic agents in one or more unit doses. In some embodiments, the kit includes one or more agents that activate latent HIV, such as one or more latency reversing agents (LRAs). In some embodiments, the kit includes one or more LRAs selected from one or more agonists or activators of Toll-like receptors (TLRs), histone deacetylase (HDAC) inhibitors, proteasome inhibitors, protein kinase C (PKC) activators, Smyd2 inhibitors, BET-bromodomain 4 (BRD4) inhibitors, ionomycin, apoptosis protein inhibitor (IAP) antagonists, and second mitochondria-derived activator of caspases (SMAC) mimetics. In some embodiments, the kit includes one or more agonists or activators of one or more Toll-like receptors (TLRs). In some embodiments, the TLR agonist or activator is selected from TLR2 agonists, TLR3 agonists, TLR4 agonists, TLR5 agonists, TLR7 agonists, TLR8 agonists, and TLR9 agonists.In some embodiments, the TLR7 agonist is selected from GS 9620 (vesatolimod), R848 (resiquimod), DS-0509, LHC-165, and TMX-101 (imiquimod), and / or the TLR8 agonist is selected from GS-9688 (selgantolimod), R848 (resiquimod), and NKTR-262 (dual TLR7 / TLR8 agonist). In some embodiments, the kit comprises one or more interleukin receptor agonists of interleukin selected from IL-2, IL-7, IL-12, and IL-15. In some embodiments, the kit comprises one or more cytokines selected from IL-2, IL-7, IL-12, IL-15, and variants thereof. In some embodiments, the kit comprises one or more innate immune activators. In some embodiments, the one or more innate immune activators comprise agonists of receptors selected from fms-related tyrosine kinase 3 (FLT3), stimulator of interferon genes (STING) receptor, DExD / H box helicase 58 (DDX58, also known as RIG-I), nucleotide-binding oligomerization domain-containing 2 (NOD2). In some embodiments, the kit comprises an agonist of fms-related tyrosine kinase 3 (FLT3). In some embodiments, the kit comprises one or more antagonists or inhibitors of inhibitory immune checkpoint proteins or receptors, and / or one or more activators or agonists of stimulatory immune checkpoint proteins or receptors. In some embodiments, the one or more immune checkpoint proteins or receptors are CD27, CD70; CD40, CD40LG; CD47, CD48(S. LAMF2), transmembrane domain and immunoglobulin domain-containing 2 (TMIGD2, CD28H), CD84 (LY9B, SLAMF5), CD96, CD160, MS4A1 (CD20), CD244 (SLAMF4); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); natural killer cell cytotoxicity receptor 3 ligand 1 (NCR3LG1, B7H6); HERV-H LTR-related 2 (HHLA2, B7H7); inducible T cell co-stimulatory molecule (ICOS, CD278); inducible T cell co-stimulatory molecule ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF8 (CD30), TNFSF8 (CD30L); TNFRSF10A (CD261, DR4, TRAILR1), TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF10B (CD262, DR5, TRAILR2), TNFRSF10 (TRAIL); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); TNFRSF17 (BCMA, CD269), TNFSF13B (BAFF); TNFRSF18 (GITR), TNFSF18 (GITRL); MHC class I polypeptide-related sequence A (MICA); MHC class I polypeptide-related sequence B (MICB); CD274 (CD274, PDL1, PD-L1); programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T lymphocyte-associated protein 4 (CTLA4, CD152); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1); poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155); PVR-related immunoglobulin domain-containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); T cell immunoglobulin and mucin domain-containing 4 (TIMD4; TIM4);Hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); lymphocyte activation 3 (LAG3, CD223); signaling lymphocyte activation molecule family member 1 (SLAMF1, SLAM, CD150); lymphocyte antigen 9 (LY9, CD229, SLAMF3); SLAM family member 6 (SLAMF6, CD352); SLAM family member 7 (SLAMF7, CD319); UL16-binding protein 1 (ULBP1); UL16-binding protein 2 (ULBP2); UL16-binding protein 3 (ULBP3); retinoic acid early transcript 1E (RAET1E; ULBP4); retinoic acid early transcript 1G (RAET1G; ULBP5); retinoic acid early transcript 1L (RAET1L; ULBP6); lymphocyte activation 3 (CD223); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR, CD158E1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314); killer cell lectin-like receptor C2 (KLRC2, CD159c, NKG2C); killer cell lectin-like receptor C3 (KLRC3, NKG2E); killer cell lectin-like receptor C4 (KLRC4, NKG2F); killer cell immunoglobulin-like receptor, one Ig domain, and long cytoplasmic tail 2 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 2 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor D1 (KLRD1); and, SLAM family member 7 (SLAMF7). In some embodiments, the kit comprises one or more blocking factors or inhibitors of one or more T cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the T cell inhibitory immune checkpoint protein or receptor is CD274 (CD274, PDL1, PD-L1); programmed cell death 1 ligand 2 (PDCD1LG2, PD-L2, CD273);Programmed cell death 1 (PDCD1, PD1, PD-1); cytotoxic T-lymphocyte-associated protein 4 (CTLA4, CD152); CD276 (B7H3); V-set domain-containing T cell activation inhibitor 1 (VTCN1, B7H4); V-set immunoregulatory receptor (VSIR, B7H5, VISTA); immunoglobulin superfamily member 11 (IGSF11, VSIG3); TNFRSF14 (HVEM, CD270), TNFSF14 (HVEML); CD272 (B and T lymphocyte associated (BTLA)); PVR-related immunoglobulin domain-containing (PVRIG, CD112R); T cell immunoreceptor with Ig and ITIM domains (TIGIT); lymphocyte activation 3 (LAG3, CD223); hepatitis A virus cellular receptor 2 (HAVCR2, TIMD3, TIM3); galectin 9 (LGALS9); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, one Ig domain, and long cytoplasmic tail 2 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 2 (KIR2DL3); and killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1). In some embodiments, the kit comprises one or more agonists or activators of one or more T cell-stimulatory immune checkpoint proteins or receptors. In some embodiments, the T cell-stimulatory immune checkpoint protein or receptor is CD27, CD70; CD40, CD40LG; inducible T cell co-stimulatory molecule (ICOS, CD278); inducible T cell co-stimulatory molecule ligand (ICOSLG, B7H2); TNF receptor superfamily member 4 (TNFRSF4, OX40); TNF superfamily member 4 (TNFSF4, OX40L); TNFRSF9 (CD137), TNFSF9 (CD137L); TNFRSF18 (GITR), TNFSF18 (GITRL); CD80 (B7-1), CD28; nectin cell adhesion molecule 2 (NECTIN2, CD112); CD226 (DNAM-1);It is selected from poliovirus receptor (PVR) cell adhesion molecule (PVR, CD155). In some embodiments, the kit further comprises one or more blocking factors or inhibitors of one or more NK cell inhibitory immune checkpoint proteins or receptors. In some embodiments, the NK cell inhibitory immune checkpoint protein or receptor is killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR, CD158E1); killer cell immunoglobulin-like receptor, one Ig domain, and long cytoplasmic tail 2 (KIR2DL1); killer cell immunoglobulin-like receptor, two Ig domains, and long cytoplasmic tail 2 (KIR2DL2); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 2 (KIR2DL3); killer cell immunoglobulin-like receptor, three Ig domains, and long cytoplasmic tail 1 (KIR3DL1); killer cell lectin-like receptor C1 (KLRC1, NKG2A, CD159A); and killer cell lectin-like receptor D1 (KLRD1, CD94). In some embodiments, the kit comprises one or more agonists or activators of one or more NK cell stimulatory immune checkpoint proteins or receptors. In some embodiments, the NK cell stimulatory immune checkpoint protein or receptor is CD16, CD226 (DNAM-1); killer cell lectin-like receptor K1 (KLRK1, NKG2D, CD314);and is selected from SLAM family member 7 (SLAMF7). In some embodiments, the one or more immune checkpoint inhibitors include protein inhibitors of PD-L1 (CD274), PD-1 (PDCD1) or CTLA4. In some embodiments, the kit includes an antibody that binds to CTLA4. In some embodiments, the proteinaceous or antibody inhibitor of CTLA4 is selected from ipilimumab, tremelimumab, BMS-986218, AGEN1181, AGEN1884, BMS-986249, MK-1308, REGN-4659, ADU-1604, CS-1002, BCD-145, APL-509, JS-007, BA-3071, ONC-392, AGEN-2041, JHL-1155, KN-044, CG-0161, ATOR-1144, PBI-5D3H5, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), XmAb-20717 (PD-1 / CTLA4), and AK-104 (CTLA4 / PD-1). In some embodiments, the proteinaceous inhibitor of PD-L1 (CD274) or PD-1 (PDCD1) is pembrolizumab, nivolumab, semiprimab, pidilizumab, AMP-224, MEDI0680 (AMP-514), spartalizumab, atezolizumab, avelumab, durvalumab, BMS-936559, CK-301, PF-06801591, BGB-A317 (tislelizumab), GLS-010 (WBP-3055), AK-103 (HX-008), AK-105, CS-1003, HLX-10, MGA-012, BI-754091, AGEN-2034, JS-001 (tripalimumab), JNJ-63723283, genolimzumab (CBT-501), LZM-009, BCD-100, LY-3300054, SHR-1201, SHR-1210 (camrelizumab), Sym-021, ABBV-181, PD1-PIK, BAT-1306, (MSB0010718C), CX-072, CBT-502, TSR-042 (dostarlimab), MS; Selected from B-2311, JTX-4014, BGB-A333, SHR-1316, CS-1001 (WBP-3155, KN-035, IBI-308 (sintilimab), HLX-20, KL-A167, STI-A1014, STI-A1015 (IMC-001), BCD-135, FAZ-053, TQB-2450, MDX1105-01, FPT-155 (CTLA4 / PD-L1 / CD28), PF-06936308 (PD-1 / CTLA4), MGD-013 (PD-1 / LAG-3), FS-118 (LAG-3 / PD-L1) MGD-019 (PD-1 / CTLA4), KN-046 (PD-1 / CTLA4), MEDI-5752 (CTLA4 / PD-1), RO-7121661 (PD-1 / TIM-3), XmAb-20717 (PD-1 / CTLA4), AK-104 (CTLA4 / PD-1), M7824 (PD-L1 / TGFβ-EC domain), CA-170 (PD-L1 / VISTA), CDX-527 (CD27 / PD-L1), LY-3415244 (TIM3 / PDL1), and INBRX-105 (4-1BB / PDL1). In some embodiments, one or more immune checkpoint inhibitors are CD274 (PDL1, PD-L1), programmed cell death 1 (PDCD1, PD1, PD-1 ), or a small molecule inhibitor of CTLA4. In some embodiments, the small molecule inhibitor of CD274 or PDCD1 is selected from GS-4224, GS-4416, INCB086550, and MAX10181. In some embodiments, the small molecule inhibitor of CTLA4 comprises BPI-002. In some embodiments, the kit further comprises one or more antiviral agents. In some embodiments, the one or more antiviral agents are selected from HIV protease inhibitors, HIV reverse transcriptase inhibitors, HIV integrase inhibitors, HIV non-catalytic site (or allosteric) integrase inhibitors, HIV entry (fusion) inhibitors, HIV maturation inhibitors, and capsid inhibitors.

[0016] Also provided are methods in a subject in need of inducing an immune response against human immunodeficiency virus (HIV), comprising administering to the subject a fusion polypeptide, a complex fusion polypeptide, a polynucleotide, a vector, a lipoplex (e.g., LNP), or an immunogenic composition as described herein. Also provided are methods in a subject in need of treating or preventing human immunodeficiency virus (HIV), comprising administering to the subject a fusion polypeptide, a complex fusion polypeptide, a vector, a lipoplex (e.g., LNP), or an immunogenic composition as described herein. In some embodiments, the method involves administering a single vector comprising one or more polynucleotides encoding a first fusion polypeptide and a second fusion polypeptide. In some embodiments, two or more fusion polypeptides, two or more complex fusion polypeptides, two or more polynucleotides encoding a fusion polypeptide, two or more viral expression vectors comprising a polynucleotide encoding a fusion polypeptide, two or more lipoplexes (e.g., LNP), or two or more immunogenic compositions as described herein are administered to the subject simultaneously or in parallel. In some embodiments, two or more fusion polypeptides, or two or more polynucleotides or two or more viral expression vectors encoding a fusion polypeptide are in the form of a bivalent antigen composition. In some embodiments, the method involves administering a first fusion polypeptide and a second fusion polypeptide, one or more polynucleotides encoding the first and second fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding the first and second fusion polypeptides, or one or more lipoplexes (e.g., LNP), wherein the first and second polypeptides comprise the following polypeptide segments linked or connected, optionally by one or more linkers, in order from the N-terminus to the C-terminus: SEQ ID NO: 6, 4, 16, and 26, and SEQ ID NO: 7, 5, 27, and 17, SEQ ID NO: 12, 24, 8, and 10, and SEQ ID NO: 9, 25, 13, and 11, SEQ ID NO: 14, 22, 18, 24, and 20, and SEQ ID NO: 15, 25, 19, 23, and 21, SEQ ID NO: 26, 16, 4, and 6, and SEQ ID NO: 7, 27, 5, and 17, SEQ ID NO: 8, 24, 12,and 10, and SEQ ID NOs: 13, 25, 9, and 11, SEQ ID NOs: 22, 24, 14, 18, and 20, and SEQ ID NOs: 25, 23, 15, 21, and 19, SEQ ID NOs: 20, 6, 4, 18, 16, and 26, and SEQ ID NOs: 7, 19, 5, 21, 27, and 17, SEQ ID NOs: 8, 24, 14, 12, 22, and 10, and SEQ ID NOs: 9, 13, 25, 23, 15, and 11, SEQ ID NOs: 18, 26, 20, 4, 6, and 16, and SEQ ID NOs: 7, 21, 17, 5, 27, and 19, SEQ ID NOs: 22, 24, 12, 14, 8, and 10, and SEQ ID NOs: 15, 25, 9, 23, 13, and 11, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 7, 21, 5, 25, 33, and 19, SEQ ID NOs: 24, 6, 4, 20, 18, and 32, and SEQ ID NOs: 8, 30, 14, 12, 26, and 10, SEQ ID NOs: 8, 30, 14, 12, 26, and 10, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 6, 20, 4, 24, 32, and 18, and SEQ ID NOs: 8, 12, 30, 26, 14, and 10, SEQ ID NOs: 7, 21, 5, 25, 33, and 19, and SEQ ID NOs: 9, 13, 31, 27, 15, and 11, SEQ ID NOs: 20, 32, 24, 4, 6, and 18, and SEQ ID NOs: 26, 30, 12, 14, 8, and 10, SEQ ID NOs: 7, 25, 19, 5, 33, and 21, and SEQ ID NOs: 15, 31, 9, 27, 13, and 11, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 26, 10, 20, and 28, SEQ ID NOs: 24, 6, 16, and 18, and SEQ ID NOs: 7, 25, 17, and 19, SEQ ID NOs: 7, 19, 17, and 25, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 24, 16, 6, and 18, and SEQ ID NOs: 27, 11, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 11, 27, 21, and 29, SEQ ID NOs: 7, 25, 17, and 19, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 20, and 28, and SEQ ID NOs: 23, 7, 21, and 29, SEQ ID NOs: 22, 20, 6, and 28, and SEQ ID NOs: 7, 21, 23, and 29, SEQ ID NOs: 26, 10, 20,and 28, and SEQ ID NOs: 21, 27, 11, and 29, SEQ ID NOs: 22, 6, 16, 20, 18, 28, 26, and 10, or SEQ ID NOs: 7, 21, 19, 17, 27, 25, 29, and 11. In some embodiments, the method involves administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipid complexes (e.g., LNP), wherein the one or more fusion polypeptides comprise an amino acid sequence of any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 70-101, 105-112, 200-209, 222-223, and 227, or consists of or consists essentially of such an amino acid sequence. In some embodiments, the method involves administering one or more fusion polypeptides, one or more polynucleotides encoding one or more fusion polypeptides, one or more vectors comprising one or more polynucleotides encoding one or more fusion polypeptides, one or more lipid complexes (e.g., LNP), wherein the one or more fusion polypeptides comprise an amino acid sequence of any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or an amino acid sequence that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% identical to any one of SEQ ID NOs: 82-83, 85-87, 98-101, 209, and 222-223, or consists of or consists essentially of such an amino acid sequence. In some embodiments, the method comprises the following first fusion polypeptide and second fusion polypeptide, one or more polynucleotides encoding the following first fusion polypeptide and second fusion polypeptide optionally linked or connected by one or more linkers, one or more polynucleotides, one or more vectors, or one or more lipid complexes (e.g.,accompanied by administering LNP): a fusion polypeptide that is the same as SEQ ID NO: 70 and 71, or any one of SEQ ID NO: 70 and 71 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 72 and 73, or any one of SEQ ID NO: 72 and 73 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 74 and 75, or any one of SEQ ID NO: 74 and 75 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 76 and 77, or any one of SEQ ID NO: 76 and 77 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 78 and 79, or any one of SEQ ID NO: 78 and 79 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 80 and 81, or any one of SEQ ID NO: 80 and 81 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 82 and 83, or any one of SEQ ID NO: 82 and 83 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical thereto; a fusion polypeptide that is the same as SEQ ID NO: 84 and 85,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or 85, SEQ ID NO: 86 and 87, or either SEQ ID NO: 86 or 87; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or 89, SEQ ID NO: 88 and 89, or either SEQ ID NO: 88 or 89; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 85, SEQ ID NO: 82 and 86, or either SEQ ID NO: 82 or 86; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 82 or 88, SEQ ID NO: 82 and 88, or either SEQ ID NO: 82 or 88; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 83 or 87, SEQ ID NO: 85 and 87, or either SEQ ID NO: 85 or 87; or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%,A fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 88 and 87, or either one of SEQ ID NO: 88 and 87 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, , a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 84 and 88, or either one of SEQ ID NO: 84 and 88 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 89, or either one of SEQ ID NO: 85 and 89 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 101, or either one of SEQ ID NO: 85 and 101 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 90 and 91, or either one of SEQ ID NO: 90 and 91 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 92 and 93, or either one of SEQ ID NO: 92 and 93 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 94 and 95, or either one of SEQ ID NO: 94 and 95 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, a fusion polypeptide that is 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 96 and 97, or either one of SEQ ID NO: 96 and 97 and at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NO: 94 and 96, or either one of SEQ ID NO: 94 and 96 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 95 and 97, or either one of SEQ ID NO: 95 and 97 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 220 and 221, or either one of SEQ ID NO: 220 and 221 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 100, or either one of SEQ ID NO: 98 and 100 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 99 and 101, or either one of SEQ ID NO: 99 and 101 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 98 and 99, or either one of SEQ ID NO: 98 and 99 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, or SEQ ID NO: 100 and 101, or either one of SEQ ID NO: 100 and 101 and each is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical. In some embodiments, the method involves administering one or more vectors or one or more lipoplexes (e.g., LNP) encoding the following first fusion polypeptide and second fusion polypeptide, optionally linked or connected by one or more linkers in the order from the N-terminus to the C-terminus: a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 70 and 71, or either one of SEQ ID NO: 70 and 71; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 71 and 70, or either one of SEQ ID NO: 71 and 70; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 72 and 73, or either one of SEQ ID NO: 72 and 73; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 73 and 72, or either one of SEQ ID NO: 73 and 72; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to SEQ ID NO: 74 and 75, or either one of SEQ ID NO: 74 and 75; a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%,A fusion polypeptide that is 98% or 99% identical, SEQ ID NO: 76 and 77, or either one of SEQ ID NO: 76 and 77, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 77 and 76, or either one of SEQ ID NO: 77 and 76, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 78 and 79, or either one of SEQ ID NO: 78 and 79, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 79 and 78, or either one of SEQ ID NO: 79 and 78, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 80 and 81, or either one of SEQ ID NO: 80 and 81, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 81 and 80, or either one of SEQ ID NO: 81 and 80, and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 83, or either one of SEQ ID NO: 82 and 83,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 83 and 82, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 84 and 85, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 85 and 84, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 86 and 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 87 and 86, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 88 and 89, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either one of SEQ ID NO: 89 and 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, orA fusion polypeptide that is 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 85 and 82, or at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 9, respectively, with either one of SEQ ID NO: 85 and 82 A fusion polypeptide that is 5%, 96%, 97%, 98% or 99% identical, SEQ ID NO: 82 and 86, or any one of SEQ ID NO: 82 and 86 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 86 and 82, or any one of SEQ ID NO: 86 and 82 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 82 and 88, or any one of SEQ ID NO: 82 and 88 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 88 and 82, or any one of SEQ ID NO: 88 and 82 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 83 and 87, or any one of SEQ ID NO: 83 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 87 and 83, or any one of SEQ ID NO: 87 and 83 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 85 and 87, or any one of SEQ ID NO: 85 and 87 and a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical respectively, SEQ ID NO: 87 and 85,or a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 87 or SEQ ID NO: 85, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 88 or SEQ ID NO: 87, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 87 or SEQ ID NO: 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to either SEQ ID NO: 84 or SEQ ID NO: 88, a fusion polypeptide that is at least 80%, 81%, 82%, 83%, 84%, 85%, 8...

Claims

[Claim 1] The invention described in the specification.

Images